<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Acta Neuropathol</journal-id>
<journal-id journal-id-type="iso-abbrev">Acta Neuropathol</journal-id>
<journal-title-group>
<journal-title>Acta Neuropathologica</journal-title>
</journal-title-group>
<issn pub-type="ppub">0001-6322</issn>
<issn pub-type="epub">1432-0533</issn>
<publisher>
<publisher-name>Springer Berlin Heidelberg</publisher-name>
<publisher-loc>Berlin/Heidelberg</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31363836</article-id>
<article-id pub-id-type="pmc">6851224</article-id>
<article-id pub-id-type="publisher-id">2049</article-id>
<article-id pub-id-type="doi">10.1007/s00401-019-02049-1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Paper</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Detrimental and protective action of microglial extracellular vesicles on myelin lesions: astrocyte involvement in remyelination failure</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lombardi</surname>
<given-names>Marta</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parolisi</surname>
<given-names>Roberta</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scaroni</surname>
<given-names>Federica</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bonfanti</surname>
<given-names>Elisabetta</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gualerzi</surname>
<given-names>Alice</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gabrielli</surname>
<given-names>Martina</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kerlero de Rosbo</surname>
<given-names>Nicole</given-names>
</name>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Uccelli</surname>
<given-names>Antonio</given-names>
</name>
<xref ref-type="aff" rid="Aff6">6</xref>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giussani</surname>
<given-names>Paola</given-names>
</name>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Viani</surname>
<given-names>Paola</given-names>
</name>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garlanda</surname>
<given-names>Cecilia</given-names>
</name>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abbracchio</surname>
<given-names>Maria P.</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chaabane</surname>
<given-names>Linda</given-names>
</name>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Buffo</surname>
<given-names>Annalisa</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fumagalli</surname>
<given-names>Marta</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Verderio</surname>
<given-names>Claudia</given-names>
</name>
<address>
<phone>+39 0250317011</phone>
<email>c.verderio@in.cnr.it</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.417728.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1756 8807</institution-id><institution>IRCCS Humanitas, </institution></institution-wrap>via Manzoni 56, 20089 Rozzano, Italy </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.418879.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 9800</institution-id><institution>CNR Institute of Neuroscience, </institution></institution-wrap>via Vanvitelli 32, 20129 Milan, Italy </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.7605.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2336 6580</institution-id><institution>Department of Neuroscience Rita Levi-Montalcini and Neuroscience Institute Cavalieri Ottolenghi, </institution><institution>University of Turin, </institution></institution-wrap>Regione Gonzole 10, 10043 Orbassano, Italy </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Department of Excellence: Department of Pharmacological and Biomolecular Sciences (DiSFeB), </institution><institution>University of Milan, </institution></institution-wrap>via Balzaretti 9, 20133 Milan, Italy </aff>
<aff id="Aff5"><label>5</label>IRCCS Fondazione Don Carlo Gnocchi, via Capecelatro 66, 20148 Milan, Italy </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.5606.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2151 3065</institution-id><institution>Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), </institution><institution>University of Genoa, </institution></institution-wrap>Largo Paolo Daneo 3, 16132 Genoa, Italy </aff>
<aff id="Aff7"><label>7</label>IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Department of Biotechnology and Translational Medicine, </institution><institution>University of Milan, </institution></institution-wrap>20090 Segrate, Italy </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.452490.e</institution-id><institution>Humanitas University, </institution></institution-wrap>via Manzoni 56, 20089 Rozzano, Italy </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.18887.3e</institution-id><institution-id institution-id-type="ISNI">0000000417581884</institution-id><institution>Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, </institution></institution-wrap>Via Olgettina Milano 58, 20132 Milan, Italy </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>30</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>30</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2019</year>
</pub-date>
<volume>138</volume>
<issue>6</issue>
<fpage>987</fpage>
<lpage>1012</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>23</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>7</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Â© The Author(s) 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Microglia are highly plastic immune cells which exist in a continuum of activation states. By shaping the function of oligodendrocyte precursor cells (OPCs), the brain cells which differentiate to myelin-forming cells, microglia participate in both myelin injury and remyelination during multiple sclerosis. However, the mode(s) of action of microglia in supporting or inhibiting myelin repair is still largely unclear. Here, we analysed the effects of extracellular vesicles (EVs) produced in vitro by either pro-inflammatory or pro-regenerative microglia on OPCs at demyelinated lesions caused by lysolecithin injection in the mouse corpus callosum. Immunolabelling for myelin proteins and electron microscopy showed that EVs released by pro-inflammatory microglia blocked remyelination, whereas EVs produced by microglia co-cultured with immunosuppressive mesenchymal stem cells promoted OPC recruitment and myelin repair. The molecular mechanisms responsible for the harmful and beneficial EV actions were dissected in primary OPC cultures. By exposing OPCs, cultured either alone or with astrocytes, to inflammatory EVs, we observed a blockade of OPC maturation only in the presence of astrocytes, implicating these cells in remyelination failure. Biochemical fractionation revealed that astrocytes may be converted into harmful cells by the inflammatory EV cargo, as indicated by immunohistochemical and qPCR analyses, whereas surface lipid components of EVs promote OPC migration and/or differentiation, linking EV lipids to myelin repair. Although the mechanisms through which the lipid species enhance OPC maturation still remain to be fully defined, we provide the first demonstration that vesicular sphingosine 1 phosphate stimulates OPC migration, the first fundamental step in myelin repair. From this study, microglial EVs emerge as multimodal and multitarget signalling mediators able to influence both OPCs and astrocytes around myelin lesions, which may be exploited to develop novel approaches for myelin repair not only in multiple sclerosis, but also in neurological and neuropsychiatric diseases characterized by demyelination.</p>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (10.1007/s00401-019-02049-1) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Microglia</kwd>
<kwd>Extracellular vesicles</kwd>
<kwd>Mesenchymal stem cells</kwd>
<kwd>Myelin lesion</kwd>
<kwd>S1P</kwd>
<kwd>Astrocytes</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>GMSI 2015</institution>
</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>FISM</institution>
</funding-source>
<award-id>2018/R/22</award-id>
<principal-award-recipient>
<name>
<surname>Verderio</surname>
<given-names>Claudia</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>MIUR</institution>
</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002803</institution-id>
<institution>Fondazione Cariplo</institution>
</institution-wrap>
</funding-source>
<award-id>2015-0910</award-id>
<principal-award-recipient>
<name>
<surname>Fumagalli</surname>
<given-names>Marta</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>Â© Springer-Verlag GmbH Germany, part of Springer Nature 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par22">Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system characterized by secondary decline in myelin repair, loss of neurons and progressive disability [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. At early disease stages, successful remyelination is sustained by oligodendrocyte precursor cells (OPCs) [<xref ref-type="bibr" rid="CR33">33</xref>]. In response to myelin damage, these cells, also called NG2-glia, proliferate and migrate to lesion sites, where they mature to new myelin-forming cells [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR69">69</xref>] leading to restoration of rapid neurotransmission and neurological remission. During disease chronicization up to progressive MS, remyelination is gradually impaired, primarily not only due to the inability of OPCs to differentiate into myelinating cells, but also resulting from inefficient OPC activation and recruitment to myelin lesions [<xref ref-type="bibr" rid="CR60">60</xref>]. At the cellular/molecular levels, the interplay between OPCs and microglia and other glial cells seems to play a key role in remyelination failure [<xref ref-type="bibr" rid="CR54">54</xref>].</p>
<p id="Par23">Microglia are the self-renewing, long-lived brain immune cells [<xref ref-type="bibr" rid="CR35">35</xref>] whose tasks are mainly related to immune response and homeostasis. Guided by local environmental signals [<xref ref-type="bibr" rid="CR57">57</xref>], microglia acquire a variety of activation states, ranging from protective [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR72">72</xref>] to harmful [<xref ref-type="bibr" rid="CR37">37</xref>] phenotypes participating in mechanisms of tissue repair as well as to injury. More than 80% of MS-specific genes identified at actively demyelinating lesions are related to microglia activation and T cell-mediated inflammation [<xref ref-type="bibr" rid="CR66">66</xref>]. Moreover, interference with microglia activation limits disease progression [<xref ref-type="bibr" rid="CR37">37</xref>], supporting a strong relationship between microglia activation and demyelination [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Importantly, the negative impact of microglia on oligodendrocytes may occur through astrocytes, recognised players in MS immunopathology [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], which are transformed to harmful A1 cells by inflammatory microglial mediators released from microglia (IL-1Î±, TNF and C1q) [<xref ref-type="bibr" rid="CR55">55</xref>]. On the other hand, microglial gene expression patterns suggest favourable microglial function, such as phagocytosis of myelin debris and release of growth factors in acute lesions and at the active edges of chronic active lesions where remyelination often takes place [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR97">97</xref>] (reviewed in [<xref ref-type="bibr" rid="CR18">18</xref>]) [<xref ref-type="bibr" rid="CR57">57</xref>]. In addition, in the absence of pro-regenerative microglia, OPC differentiation becomes less efficient, eventually resulting in impaired myelin repair [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR87">87</xref>], whereas a switch of microglia to an anti-inflammatory phenotype promotes remyelination and ameliorates the clinical signs of experimental autoimmune encephalomyelitis (EAE) [<xref ref-type="bibr" rid="CR100">100</xref>], an animal model of MS. Despite the demonstration of both detrimental and beneficial effects of microglia on myelin lesion, the mode(s) of action of these cells in aiding or inhibiting remyelination is still largely unclear.</p>
<p id="Par24">Extracellular vesicles (EVs), including ectosomes/microvesicles shed from the plasma membrane and exosomes originating from multivesicular bodies, have recently raised large interest as powerful mediators of intercellular communication between microglia and brain cells [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. Production of microglial EVs dramatically increases under brain inflammation [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR95">95</xref>] reflecting the extent of microglia activation. Following interaction with the recipient cells, microglia-derived EVs activate contact-mediated signaling pathways [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] and/or deliver genetic information [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR95">95</xref>], thus profoundly influencing the molecular configuration and function of the target cells. Specifically, microglia-derived EVs propagate an activation signal to astrocytes and to other microglia [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR95">95</xref>] and enhance excitatory neurotransmission [<xref ref-type="bibr" rid="CR1">1</xref>]. However, whether microglial EVs play a role in the cross-talk between microglia and OPCs or not is still unknown.</p>
<p id="Par25">Here, we have investigated the effects on OPCs of EVs released in vitro from either pro-inflammatory or pro-regenerative microglia both in vivo in the lysolecithin (LPC) mouse model of focal demyelination and in vitro in primary OPC cultures. Although classification in inflammatory and pro-regenerative cells underestimates the complexity of microglial activation, such a definition provides a useful framework for investigating the impact of microglia on OPCs. To induce pro-regenerative traits, microglia were exposed to the classical polarising agent IL-4 or to immunosuppressive mesenchymal stem cells (MSCs) [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR101">101</xref>], while inflammatory state was obtained through stimulation with inflammatory cytokines.</p>
<p id="Par26">We found that EVs produced by inflammatory microglia led to blockade of OPC differentiation to myelin-forming cells. Conversely, EVs released from microglia exposed to MSCs promoted remyelination. Biochemical fractionation combined with in vitro experiments revealed a major contribution of the inflammatory cargo of EVs to blocking OPC maturation, while surface lipids were identified as responsible factors for the pro-myelinating action of EVs. Although the type of lipids driving OPC differentiation still remains to be fully defined, sphingolipid sphingosine 1 phosphate (S1P) was unveiled as the key molecule favouring OPC migration, the first fundamental step in the remyelination process.</p>
</sec>
<sec id="Sec2">
<title>Materials and methods</title>
<sec id="Sec3">
<title>Lysolecithin-induced myelin lesions</title>
<p id="Par27">Demyelinating lesions were induced in the corpus callosum (CC) of adult (2.5â4Â months old) and aged (8â12Â months old) male C57BL/6 mice by stereotaxic unilateral injection of 1Â Î¼l of 2% lysolecithinto the mouse corpus callosum (CC, coordinates: 1.0Â mm lateral, 1.0Â mm rostral to Bregma and 1.5Â mm deep). Three days post lesion (dpl), 2Â ÃÂ 10<sup>8</sup> EVs, produced by 1.5Â ÃÂ 10<sup>6</sup> microglia and dissolved in 150Â Âµl of sterile saline, were delivered to the mice with mini-pumps (Alzet osmotic pumps 1007D) at the same coordinates over 4Â days at 1.5Â ÂµlÂ h<sup>â1</sup> delivery rate. To limit EV degradation, minipumps were filled with freshly isolated EVs and implanted within a few hours. Controls were obtained with delivery of saline solution. To examine cell proliferation, we used the thymidine analog 5-bromo-2-deoxyuridine (BrdU), which is incorporated into DNA during S-phase of the cell cycle and remains in the DNA even when the cell has exited the active phases of the cell cycle. Mice were i.p. injected with BrdU (100Â mgÂ kg<sup>â1</sup> body weight; 2 pulses 2Â h apart) 1Â day from the start of EVs delivery. A separate group of mice received a single injection of 6.6Â ÃÂ 10<sup>7</sup> EVs, released from 0.5Â ÃÂ 10<sup>6</sup> microglia and dissolved in 1Â Âµl of sterile saline, at the site of lesion at 7Â dpl. Controls were obtained by injecting saline. Mice were transcardially perfused with 4% paraformaldehyde in phosphate buffer (PB 0.1Â M, pH 7.4) at 4Â days after mini-pump implantation or at 3Â days after acute injection and brains were post-fixed overnight and cryoprotected in 30% sucrose in 0.12Â MÂ PB. Surgery and perfusion were carried out under deep general anaesthesia (ketamine, 100Â mgÂ kg<sup>â1</sup>, Ketavet, Bayern, Leverkusen, Germany; xylazine, 5Â mgÂ kg<sup>â1</sup>, Rompun, Bayer, Leverkusen, Germany). All animal procedures were performed in accordance with the European directive (2010/63/EU) and the Italian Law for Care and Use of Experimental Animals (DL116/92; DL26/2014), and the studies were authorised by the Italian Ministry of Health (Authorization: 1112-2016PR) and the Bioethical Committee of the University of Turin.</p>
</sec>
<sec id="Sec4">
<title>Electron microscopy of myelin lesions</title>
<p id="Par28">Conventional electron microscopy was carried out as in [<xref ref-type="bibr" rid="CR5">5</xref>]. LPC-lesioned old mice injected with saline, i-EVs or MSC-EVs were perfused transcardially with PB followed by 2% paraformaldehyde and 2.5% glutaraldehyde in PB. The brain was removed and post-fixed overnight at 4Â Â°C in the same fixative. Vibratome sagittal sections (250Â Î¼m thick) were cut, and post-fixed with 1% osmium tetroxide for 1Â h at 4Â Â°C, then stained with uranyl acetate replacement stain (Electron Microscopy Sciences, USA). After dehydration in ethanol, samples were cleared in propylene oxide and embedded in Araldite (Fluka, Saint Louis, USA). Semithin sections (1Â Î¼m thick) were obtained at the ultramicrotome (Ultracut UCT, Leica, Wetzlar, Germany), stained with 1% toluidine blue and 2% borate in distilled water and then observed under a light microscope for precise lesion location. Ultrathin sections (70â100Â nm) were examined under a transmission electron microscope (JEOL, JEM-1010, Tokyo, Japan) equipped with a Mega-View-III digital camera and a Soft-Imaging-System (SIS, MÃ¼nster, Germany) for computerized acquisition of the images. Profiles of microglia, astrocytes, oligodendrocytes and myelinated axons were identified according to well established criteria [<xref ref-type="bibr" rid="CR78">78</xref>]. Microglia were distinguished by their specific ultrastructural features including frequent stretches of endoplasmic reticulum and a condensed, electron-dense cytoplasm [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. In the core of the lesion, electron micrographs were taken at 25Â K magnification and ImageJ software (<ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</ext-link>) was used to measure the proportion of myelinated axons (on at least 150 axons/animal) and perform the measurements needed to obtain G-ratios, the ratios of theÂ axonalÂ diameter (d white, Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>k) to the outer fibre diameter including theÂ myelinÂ sheathÂ (d yellow, Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>k), of at least 50 myelinated axons/animal. Quantifications were performed on three mice (8â12Â months old) per experimental condition.</p>
</sec>
<sec id="Sec5">
<title>Immunohistochemistry</title>
<p id="Par29">Brains were processed according to standard immunohistochemical procedures [<xref ref-type="bibr" rid="CR9">9</xref>]. They were cut into 30Â Âµm-thick coronal sections, collected in PBS and stained with the antibodies reported in the TableÂ <xref ref-type="table" rid="Tab1">1</xref>. OPCs were labelled by anti-NG2 antibodies while more mature cells were detected by anti-CC1 serum. Anti-Olig2 and anti-Sox10 stained the whole oligodendrocyte lineage. Anti-MBP antibodies labelled myelin. To follow cell proliferation, we used anti-BrdU. DAPI or Hoechst33258 were used to label nuclei. Anti-GFAP, anti-PTX3 and anti-C3 were used to label astrocytes, Iba-1 to reveal microglia. Sections were incubated overnight with primary antibodies at 4Â Â°C in PBS with 1.5% donkey serum, 2% bovine serum albumin and 0.5% Triton X-100. Sections were then exposed for 2Â h at room temperature to secondary anti-rabbit, anti-chicken antibodies conjugated with Alexa Fluor 488 or anti-rabbit antibodies conjugated with Alexa Fluor 546 (1:500; Invitrogen, Waltham, MA, USA), anti-mouse, anti rabbit antibodies conjugated with Cy3 (1:500; Jackson ImmunoResearch, West Grove, PA, USA), anti-goat antibodies conjugated with Alexa Fluor 649 (1:500; Invitrogen) or anti-mouse antibodies conjugated with Cy5 (1:500; Jackson ImmunoResearch). Double staining with rabbit anti-GFAP and rabbit anti-PTX3/anti-C3 was performed using the High Sensitivity Tyramide-Rhodaminate Signal Amplification kit (Perkin-Elmer, Monza, Italy) following the manufacturerâs instructions. Following counterstaining with 4,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich Co., St. Louis, MO, USA) or Hoechst 33258 (Life Technologies, Monza, Italy) to label nuclei, slides were coverslipped with Mowiol (Millipore, Burlington, MA, USA) or with a fluorescent mounting medium from Dako (Milan, Italy). All images were collected using a Nikon Eclipse 90i confocal microscope (Nikon, Melville, NY, USA), or using a Zeiss LSM 800 confocal microscope (Carl Zeiss S.p.A, Milano, Italy). Adobe Photoshop 6.0 (Adobe Systems) was used to adjust image contrast and assemble the final plates. Measurements were derived from at least three sections per mice. Three to five animals were analysed per each time point or experimental condition. Image analysis was performed with the Image J software to quantify the proportion of NG2 or MBP-stained pixels throughout the entire lesioned area in each section [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Density of oligodendroglial, proliferative cells and PTX3- and C3-positive astrocytes in the lesion was calculated as number of cellsÂ mm<sup>â2</sup>, using the ImageJ software.<table-wrap id="Tab1"><label>TableÂ 1</label><caption><p>List of primary antibodies used for immunohistochemistry (IHC), immunofluorescence (ICC) and western-blot (WB) analyses</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Antibody</th><th align="left">Host</th><th align="left">Supplier</th><th align="left">IHC dilution</th><th align="left">ICC dilution</th><th align="left">WB dilution</th></tr></thead><tbody><tr><td align="left">Anti-NG2</td><td align="left">Rabbit</td><td align="left">Millipore (Burlington, MA, USA)</td><td align="left">1:200</td><td align="left">1:100</td><td align="left"></td></tr><tr><td align="left">Anti-CC1</td><td align="left">Mouse</td><td align="left">Millipore (Burlington, MA, USA)</td><td align="left">1:1500</td><td align="left"></td><td align="left"></td></tr><tr><td align="left">Anti-CNPase</td><td align="left">Rabbit</td><td align="left">SantaCruz (Dallas, Texas)</td><td align="left"></td><td align="left"></td><td align="left">1:250</td></tr><tr><td align="left">Anti-Olig2</td><td align="left">Rabbit</td><td align="left">Millipore (Burlington, MA, USA)</td><td align="left">1:500</td><td align="left">1:300</td><td align="left"></td></tr><tr><td align="left">Anti-SOX-10</td><td align="left">Goat</td><td align="left">SantaCruz (Dallas, Texas)</td><td align="left">1:200</td><td align="left"></td><td align="left"></td></tr><tr><td align="left">Anti-MBP</td><td align="left">Rat</td><td align="left">AbD Serotec (Oxford, UK)</td><td align="left"></td><td align="left">1:200</td><td align="left"></td></tr><tr><td align="left">Anti-MBP</td><td align="left">Rat</td><td align="left">Covance (Princeton, NJ)</td><td align="left">1:1000</td><td align="left"></td><td align="left"></td></tr><tr><td align="left">Anti-MBP</td><td align="left">Rat</td><td align="left">Millipore (Burlington, MA, USA)</td><td align="left"></td><td align="left">1:200</td><td align="left">1:500</td></tr><tr><td align="left">Anti-BrdU</td><td align="left">Rat</td><td align="left">Abcam (Cambridge, UK)</td><td align="left">1:500</td><td align="left"></td><td align="left"></td></tr><tr><td align="left">Anti-pentraxin3</td><td align="left">Rabbit</td><td align="left">Home-made generated as previously described [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td align="left">1:250</td><td align="left"></td><td align="left"></td></tr><tr><td align="left">Anti-C3</td><td align="left">Rabbit</td><td align="left">Dako (Milan, Italy)</td><td align="left">1:250</td><td align="left"></td><td align="left"></td></tr><tr><td align="left">Anti-GFAP</td><td align="left">Rabbit</td><td align="left">Dako (Milan, Italy)</td><td align="left">1:30,000 with amplification kit</td><td align="left"></td><td align="left"></td></tr><tr><td align="left">Anti-GFAP</td><td align="left">Mouse</td><td align="left">Sigma-Aldrich (Milan, Italy)</td><td align="left"></td><td align="left">1:100</td><td align="left"></td></tr><tr><td align="left">Anti- Neurofilaments (SMI32)</td><td align="left">Mouse</td><td align="left">Cell Signaling (Beverly, MA, USA)</td><td align="left"></td><td align="left">1:500</td><td align="left"></td></tr><tr><td align="left">Anti- Neurofilaments (SMI31)</td><td align="left">Mouse</td><td align="left">Cell Signaling (Beverly, MA, USA)</td><td align="left"></td><td align="left">1:500</td><td align="left"></td></tr><tr><td align="left">Anti-Î±-tub</td><td align="left">Mouse</td><td align="left">Sigma-Aldrich</td><td align="left"></td><td align="left"></td><td align="left">1:2000</td></tr><tr><td align="left">Anti-GSTpi</td><td align="left">Rabbit</td><td align="left">MBL International Corporation (Sunnyvale, CA)</td><td align="left"></td><td align="left"></td><td align="left">1:500</td></tr><tr><td align="left">Anti-GPR17</td><td align="left">Rabbit</td><td align="left">Home-made generated as previously described, Ciana 2006</td><td align="left"></td><td align="left"></td><td align="left">1:1000</td></tr><tr><td align="left">Anti-GPR17</td><td align="left">Rabbit</td><td align="left">Cayman Chemical (Michigan, USA)</td><td align="left"></td><td align="left">1:100</td><td align="left"></td></tr><tr><td align="left">Anti-GFP</td><td align="left">Chicken</td><td align="left">AVES Labs</td><td align="left">1:700</td><td align="left">1:1400</td><td align="left"></td></tr><tr><td align="left">Anti-GFP</td><td align="left">Rabbit</td><td align="left">Life Technologies (Monza, Italy)</td><td align="left"></td><td align="left"></td><td align="left">1:3000</td></tr><tr><td align="left">Anti-Iba1</td><td align="left">Rabbit</td><td align="left">Wako Chemicals (Richmond, VA)</td><td align="left">1:1000</td><td align="left"></td><td align="left"></td></tr><tr><td align="left">4â²,6-Diamidino-2-phenylindole DAPI</td><td align="left"></td><td align="left">Fluka (Buche, Switzerland)</td><td align="left">1:1000</td><td align="left"></td><td align="left"></td></tr><tr><td align="left">DAPI</td><td align="left"></td><td align="left">Molecular Probes (Life Technologies, Monza, Italy)</td><td align="left"></td><td align="left">1:20.000</td><td align="left"></td></tr><tr><td align="left">Hoechst 33258</td><td align="left"></td><td align="left">Life Technologies (Monza, Italy)</td><td align="left">1:50,000</td><td align="left">1:10,000</td><td align="left"></td></tr><tr><td align="left">Anti-Alix</td><td align="left">Rabbit</td><td align="left">Covalab (Villeurbanne, France)</td><td align="left"></td><td align="left"></td><td align="left">1:500</td></tr><tr><td align="left">Anti-Flotilin 2</td><td align="left">Mouse</td><td align="left">BD transduction (San Jose, CA)</td><td align="left"></td><td align="left"></td><td align="left">1:1000</td></tr><tr><td align="left">Anti-GAPDH</td><td align="left">Rabbit</td><td align="left">Synaptic Systems (Goettingen, Germany)</td><td align="left"></td><td align="left"></td><td align="left">1:1000</td></tr><tr><td align="left">Anti-GS28</td><td align="left">Mouse</td><td align="left">BD transduction (San Jose, CA)</td><td align="left"></td><td align="left"></td><td align="left">1:1000</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="Sec6">
<title>Magnetic resonance imaging (MRI)</title>
<p id="Par30">In vivo MRI was performed using a 7 T scanner (Bruker-Biospin) equipped with a radiofrequency coil for mouse. Mice were anaesthetized with an intramuscular injection of Ketamine (100Â mgÂ kg<sup>â1</sup>; Ketavet, Bayern, Leverkusen, Germany) mixed with xylazine (5Â mgÂ kg<sup>â1</sup>; Rompun, Bayer, Leverkusen, Germany). High Resolution coronal and sagittal images, T2 weighted (TR/TEâ=â3000/48Â ms, slice thicknessâ=â0.7Â mm, pixelâ=â78Â ÃÂ 80Â Âµm) were acquired to localise lesions in the corpus callosum. Diffusion tensor imaging (DTI: 30 directions, <italic>b</italic>â=â1000Â sÂ mm<sup>â2</sup>) was also used to measure water molecule diffusivity across white matter fibres to further characterise CC lesions.</p>
</sec>
<sec id="Sec7">
<title>Primary cultures</title>
<p id="Par31">Mixed glial cell cultures, containing both astrocytes and microglia, were established from rat SpragueâDawley pups (P2) (Charles River, Lecco, Italy) and maintained for 10Â days in the presence of South American foetal bovine serum (Life Technologies, Monza, Italy) that optimises microglia expansion or foetal bovine serum (EuroClone, Milan, Italy) which favours OPC proliferation.</p>
<sec id="Sec8">
<title>Microglia</title>
<p id="Par32">Microglia were harvested by orbital shaking for 40Â min at 1300 r.p.m. and re-plated on poly-<sc>l</sc>-ornithine-coated tissue culture dishes (50Â Î¼gÂ ml<sup>â1</sup>, Sigma-Aldrich, Milan, Italy). To minimise the activation, pure microglia (&gt;â98%, [<xref ref-type="bibr" rid="CR75">75</xref>] were kept for 24Â h in low-serum (1%) medium. Cells were then stimulated with a cocktail of Th1 cytokines, i.e. 20Â ngÂ ml<sup>â1</sup> IL-1Î² (Peprotech, Milan, Italy), 20Â ngÂ ml<sup>â1</sup> TNF-Î± (Peprotech, Milan, Italy) and 25Â ngÂ ml<sup>â1</sup> IFN-É£ (Sigma Aldrich, Milan, Italy), or with 20Â ngÂ ml<sup>â1</sup> IL-4 for 48Â h (R&amp;D, Milan, Italy). In addition, microglia were co-cultured in transwell with MSCs at a microglia-to-MSCs ratio of 1:1 for 48Â h in the presence of Th1 cytokines. MSCs were plated on the filter of the upper chamber and microglia in the lower chamber of the transwell. At the end of treatment, MSCs were removed, microglia were washed and stimulated with ATP to increase EV production [<xref ref-type="bibr" rid="CR75">75</xref>]. To obtain GFP-labelled EVs, microglia were established from GFP-transgenic rats expressing GFP under the chicken beta actin promoter [<xref ref-type="bibr" rid="CR68">68</xref>]. Indeed, GFP is included in EVs released by GFP-positive microglia (Suppl. FigureÂ 3h, Online resource).</p>
</sec>
<sec id="Sec9">
<title>OPCs</title>
<p id="Par33">After microglia removal, OPCs growing on top of astrocyte monolayer were isolated by shaking cells on an orbital shaker at 200Â rpm for 3Â h and incubated on an uncoated Petri dish for 1Â h to further eliminate microglia. Pure OPCs (&gt;â95% [<xref ref-type="bibr" rid="CR32">32</xref>] were seeded onto poly-<sc>d</sc>,<sc>l</sc>-ornithine-coated glass coverslips or plates (50Â Î¼gÂ ml<sup>â1</sup>, Sigma-Aldrich, Milan, Italy) in Neurobasal (Life Technologies, Monza, Italy) supplemented with 2% B27 (Life Technologies, Monza, Italy), 2Â mMÂ <sc>l</sc>-glutamine (EuroClone, Milan, Italy), 10Â ngÂ ml<sup>â1</sup> human platelet-derived growth factor BB (Sigma-Aldrich, Milan, Italy), and 10Â ngÂ ml<sup>â1</sup> human basic fibroblast growth factor (Space Import Export, Milan, Italy), to promote proliferation (proliferating medium). After 3Â days, cells were either detached with accutase (Millipore, Burlington, MA, USA) and used for migration assay, or switched to a Neurobasal medium lacking growth factors and supplemented with triiodothyronine T3 (10Â ngÂ ml<sup>â1</sup>, Sigma Aldrich, Milan, Italy) to allow differentiation (differentiating medium).</p>
</sec>
<sec id="Sec10">
<title>Dorsal root ganglion (DRG)-OPC co-cultures</title>
<p id="Par34">DRG-OPC co-cultures were prepared according to a previously described protocol [<xref ref-type="bibr" rid="CR31">31</xref>]. Briefly, DRG from E14.5 mouse embryos were plucked off from spinal cord, put in culture (1 DRG/coverslip) in Neurobasal supplemented with B27 in the presence of nerve growth factor (NGF) (100Â ngÂ ml<sup>â1</sup>; Harlan, Milan, Italy) and cycled with fluorodeoxyuridine (10Â Î¼M; Sigma Aldrich, Milan, Italy) to eliminate all non-neuronal cells. After 20Â days, when neurites were well extended radially from DRG explants, 35Â ÃÂ 10<sup>3</sup> OPCs were added to each DRG in culture and kept in Minimum essential media MEM (Life Technologies Monza, Italy) supplemented with glucose (4Â gÂ l<sup>â1</sup>; Sigma Aldrich, Milan, Italy), 10% FBS and 2Â mMÂ <sc>l</sc>-glutamine (EuroClone, Milan, Italy). Myelination was induced the following day by the addition of recombinant chimeric tyrosine kinase receptor TrkA Fc (1Â Î¼gÂ ml<sup>â1</sup>; Sigma Aldrich, Milan, Italy) to the culture medium.</p>
</sec>
<sec id="Sec11">
<title>Astrocyte-OPC co-cultures</title>
<p id="Par35">Purified astrocytes were isolated from P2 rat whole brains by magnetic-activated cell sorting (MACS) (Miltenyi Biotec, Bergisch Gladbach, Germany) with anti-GLAST (ACSA 1) MicroBeads according to the manufacturerâs instructions. After 1Â week, OPCs were plated on top of astrocytes at an astrocyte-to-OPC ratio of 1:1. In a set of experiments astrocytes were isolated from P2 mouse whole brains and cultured alone for qPCR analysis of specific markers for A1 and A2 astrocytes.</p>
</sec>
<sec id="Sec12">
<title>MSCs</title>
<p id="Par36">MSCs were prepared and expanded as described previously [<xref ref-type="bibr" rid="CR102">102</xref>]. Briefly, marrow cells were flushed out from tibias and femurs of 6- to 8-week-old C57BL/6J mice and cultured in plastic plates as adherent cells using murine Mesencult as medium (Stem Cell Technologies, Vancouver, BC, Canada). Medium was refreshed every 3Â days until cells reached 80% confluence. Following treatment with 0.05% trypsin solution containing 0.02% EDTA (Euroclone, Milan, Italy), the cells were plated in 75Â cm<sup>2</sup> flask at the density of 4Â ÃÂ 10<sup>5</sup> cells. Mature MSCs, obtained after four to five passages in culture, were defined by the expression of CD9, Sca-1, CD73, and CD44 and the lack of the hematopoietic markers CD45, CD34, and CD11b on their surface, and their immunosuppressive activity was verified in T cell proliferation assays [<xref ref-type="bibr" rid="CR102">102</xref>].</p>
</sec>
</sec>
<sec id="Sec13">
<title>RNA isolation and qRT-PCR</title>
<p id="Par37">Total RNA was isolated from rat primary microglia using Direct-zolâ¢ RNA MiniPrep (Zymo Research, Irvine, CA, USA) following the manufacturerâs protocol. cDNA synthesis was performed using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) and Random Hexamers as primer. The resulting cDNAs were amplified using TaqMan<sup>Â®</sup> Gene Expression Assay (Applied Biosystems, Foster City, CA, USA) using QuantStudioâ¢5 (ThermoFisher Scientific, Waltham, MA, USA) real-time PCR system. The mRNA expression was normalised to the label of Rpl13 (Ribosomal Protein L13) mRNA. Data obtained were quantified using the 2<sup>âÎÎCT</sup> method [<xref ref-type="bibr" rid="CR56">56</xref>]. Q-PCR for A1 and A2 markers was performed on murine astrocytes with the Luna Universal Probe qPCR Master Mix (M3004S, New England Biolabs) using the StepOneâ¢ Plus Real-Time PCR System (Life Technologies, Monza, Italy). The expression of selected genes was normalized to the expression of the housekeeping gene Î²-actin. The list of primers used can be found in TableÂ <xref ref-type="table" rid="Tab2">2</xref>.<table-wrap id="Tab2"><label>TableÂ 2</label><caption><p>List of gene expression assays for qPCR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Gene symbol</th><th align="left">Name</th><th align="left">Taqman assay</th></tr></thead><tbody><tr><td align="left">Arg 1</td><td align="left">Arginase 1</td><td align="left">Rn00691090_m1</td></tr><tr><td align="left">C1q</td><td align="left">Complement C1q</td><td align="left">Rn01519903_m1</td></tr><tr><td align="left">IL1-a</td><td align="left">Interleukin 1 Alpha</td><td align="left">Rn00566700_m1</td></tr><tr><td align="left">IL1-Î²</td><td align="left">Interleukin 1 Beta</td><td align="left">Rn00580432_m1</td></tr><tr><td align="left">iNOS</td><td align="left">Nitric Oxide Synthase 2</td><td align="left">Rn00561646_m1</td></tr><tr><td align="left">Rpl13a</td><td align="left">Ribosomal Protein L13</td><td align="left">Rn00821946_g1</td></tr><tr><td align="left">Socs-3</td><td align="left">Suppressor Of Cytokine Signaling 3</td><td align="left">Rn00585674_s1</td></tr><tr><td align="left">TNF-Î±</td><td align="left">Tumour Necrosis Factor</td><td align="left">Rn99999017_m1</td></tr><tr><td align="left">Amigo 2</td><td align="left">Adhesion Molecule With Ig Like Domain 2</td><td align="left">04688058001</td></tr><tr><td align="left">Î²-Actin</td><td align="left">Actin Beta</td><td align="left">04688635001</td></tr><tr><td align="left">CD14</td><td align="left">Monocyte Differentiation Antigen CD14</td><td align="left">04687574001</td></tr><tr><td align="left">Ptx3</td><td align="left">Pentraxin 3</td><td align="left">04686993001</td></tr><tr><td align="left">Tm4sf1</td><td align="left">Transmembrane 4 L Six Family Member 1</td><td align="left">04687990001</td></tr><tr><td align="left">Serping1</td><td align="left">Serpin Family G Member 1</td><td align="left">04689011001</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="Sec14">
<title>EV isolation and quantification</title>
<p id="Par38">EVs were isolated from microglia exposed to Th1 cytokine cocktail (i-EVs), IL-4 (IL4-EVs) or MSC (MSC-EVs). To isolate EVs, polarised microglia were stimulated with 1Â mM ATP for 30Â min in KRH (125Â mM NaCl, 5Â mM KCl, 1.2Â mM MgSO<sub>4</sub>, 1.2Â mM KH<sub>2</sub>PO, 2Â mM CaCl<sub>2</sub>, 6Â mM <sc>d</sc>-glucose, and 25Â mM HEPES/NaOH, pH 7.4). The culture supernatant was collected and released EVs were pelleted at 100Â kÂ g after pre-clearing from cells and debris at 300Â g, as previously described [<xref ref-type="bibr" rid="CR34">34</xref>]. In some experiments, an ectosome-enriched fraction was pelleted at 10Â kÂ g. EV pellets were resuspended and used immediately after isolation. The number and dimension of EVs were assessed using NanoSight NS300 (NanoSight, UK) configured with a 488-nm laser and SCMOS camera. Videos were collected and analysed using the NTA-software (version 2.3), with the minimal expected particle size, minimum track length, and blue setting, all set to automatic. Camera shutter speed was fixed at 15Â ms and camera gain was set to 300. Room temperature was ranging from 25 to 28Â Â°C. EV pellets were re-suspended in 800Â Î¼l of 0.1Â Î¼m-filtered sterile KRH and four recordings of 30Â s were performed for each sample.</p>
<p id="Par39">EVs were destroyed by hypo-osmotic stress and re-pelleted to remove their luminal cargo as previously described [<xref ref-type="bibr" rid="CR34">34</xref>]. For biochemical fractionation of EVs, total lipids were extracted with 2:1 (by volume) of chloroform and methanol. The lipid fraction was evaporated under a nitrogen stream, dried for 1Â h at 50Â Â°C and resuspended in PBS at 40Â Â°C in order to obtain multilamellar vesicles. Small unilamellar vesicles were obtained by sonicating multilamellar vesicles, following the procedure of [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
</sec>
<sec id="Sec15">
<title>Quantification of sphingolipid content in EVs</title>
<p id="Par40">[<sup>3</sup>H] Sphingosine ([<sup>3</sup>H]Sph) was stocked in absolute ethanol. For the quantification of sphingolipid content in EVs, 1Â ÃÂ 10<sup>6</sup> microglia were pulsed with [<sup>3</sup>H]Sph (0.3Â ÂµCiÂ ml<sup>â1</sup>) for 24Â h followed by a 48-h chase in order to obtain a [<sup>3</sup>H]GM3/[<sup>3</sup>H]SM ratio corresponding to that of endogenous compounds (data not shown), an index for a steady-state labelling of cell sphingolipids [<xref ref-type="bibr" rid="CR96">96</xref>]. At the end of the chase, microglia were stimulated with ATP, EVs were pelleted and the cells were washed twice with PBS at 4Â Â°C and harvested. Total lipids were extracted from both EVs and cells and processed as previously described [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. The organic phase and the aqueous phase were analysed by high-performance thin-layer chromatography (HPTLC) using chloroform/methanol/water (55:20:3 by volume) and butanol/acetic acid/water (3:1:1 by volume) as the solvent systems.</p>
</sec>
<sec id="Sec16">
<title>Raman spectroscopy</title>
<p id="Par41">The Raman analysis was performed following a previously described protocol [<xref ref-type="bibr" rid="CR40">40</xref>]. Briefly, freshly isolated EVs were laid on a calcium fluoride slide and allowed to air dry. All of the measurements were performed with a Raman microspectroscope (LabRAM Aramis, Horiba JobinâYvon S.A.S, Lille, France) equipped with a laser line operating at 532Â nm and a Peltier-cooled CCD detector. Acquisitions were performed with 50X objective (NA 0.75, Olympus, Tokyo, Japan), 1800 groovesÂ mm<sup>â1</sup> diffraction grating, 400Â Î¼m entrance slit and confocal mode (600Â Î¼m pinhole) in the spectral ranges 600â1800Â cm<sup>â1</sup> and 2600â3200Â cm<sup>â1</sup>. Accumulation times were 2Â ÃÂ 30Â s per spectrum. Silicon reference sample was used for the instrument calibration. At least 30 independent replicates of the Raman spectra were obtained for every EV type. After acquisition, polynomial baseline correction and unit vector normalisation were performed before the multivariate statistical analysis.</p>
</sec>
<sec id="Sec17">
<title>OPC migration assay</title>
<p id="Par42">Migration of OPCs was performed in Boyden chambers (8Â Î¼m pore size filter; Constar, Corning, NY, USA) as previously described [<xref ref-type="bibr" rid="CR11">11</xref>]. Briefly, the chamber was nested inside the well of 24-well plates and 5Â ÃÂ 10<sup>4</sup>Â OPCs were seeded in the top of each insert with 200Â Î¼l of neurobasal medium. The bottom well was filled with 600Â Î¼l of medium containing EVs released from 1Â ÃÂ 10<sup>5</sup> microglia (~â4Â ÃÂ 10<sup>8</sup> EVsÂ ml<sup>â1</sup>). The chemotactic agent sphingosine-1 phosphate (S1P) (100Â nM) was used as positive control. After 16Â h, non-migrated cells were removed from the top compartment with a cotton swab, whereas cells that had migrated to the lower side of the filter were fixed with 4% paraformaldehyde and stained with Hoechst33258 (Life Technologies, Monza, Italy). Images were acquired at 20Ã magnification under an inverted fluorescence microscope (200Â M; Zeiss, Oberkochen, Germany) and cells were counted using ImageJ cell counter plugin in 45 random fields per well. All conditions were run in triplicate. Data are expressed as a percentage of basal migration that is the migration of OPCs without chemoattractant.</p>
</sec>
<sec id="Sec18">
<title>EV delivery by optical manipulation</title>
<p id="Par43">An IR laser beam (1064Â nm, CW) for trapping was coupled into the optical path of an inverted microscope (Axiovert 200Â M, Zeiss, Oberkochen, Germany) through the right port of the microscope. The trapping beam was directed to the microscope lens (Zeiss 63X, NA 1.4) by the corresponding port mirror (100%) and the tube lens. Optical trapping and manipulation of EVs were performed following the approach previously described [<xref ref-type="bibr" rid="CR73">73</xref>]. Immediately before recording, EVs were added in the temperature-controlled recording chamber, where OPCs plated on glass coverslips were maintained in 400Â Î¼l of Neurobasal medium with B27. As soon as an EV appeared in the recording field, it was trapped and positioned on a selected OPC by moving the cell stage horizontally and the microscope lens axially. After about 30Â s from initial contact, the laser was switched off to prove EV-OPC interaction, as previously described [<xref ref-type="bibr" rid="CR73">73</xref>]. During the experiments, OPCs were live-imaged with a spinning disk confocal microscope (UltraVIEW acquisition system, Perkin Elmer Waltham, MA, USA) using a digital camera (High Sensitivity USB 3.0 CMOS Camera 1280Â ÃÂ 1024 Global Shutter Monochrome Sensor, Thorlabs, Newton, NJ, USA) at a frame rate of 2Â Hz.</p>
</sec>
<sec id="Sec19">
<title>OPC proliferation assay</title>
<p id="Par44">One day after plating on glass coverslips, OPCs were co-exposed to EVs derived from twice as many microglia (~â2Â ÃÂ 10<sup>7</sup> EVs/500Â Âµl) and to the thymidine analog EdU (Click-iT<sup>Â®</sup> EdU Assay, Life Technologies, Monza, Italy) for 24Â h in proliferating medium. Cells were fixed with 4% paraformaldehyde and stained for EdU following the manufacturerâs instructions. Coverslips were then incubated with DAPI (1:20000, Molecular Probes, Life Technologies) to reveal total nuclei and mounted with a fluorescent mounting medium (Dako, Milan, Italy). 40â50 fields per coverslip were imaged at 20Ã magnification under an inverted fluorescence microscope (200Â M Zeiss, Oberkochen, Germany) connected to a PC computer equipped with the Axiovision software (Zeiss). OPC proliferation was assessed by quantifying EdU-DAPI double positive nuclei in at least three coverslips/condition, using ImageJ cell counter plugin. Cells with nuclei larger than 15Â Î¼m, belonging to astrocytes occasionally present in the cultures, were excluded from the analysis.</p>
</sec>
<sec id="Sec20">
<title>OPC differentiation assay</title>
<p id="Par45">OPCs were kept for 3Â days in proliferating medium, shifted to differentiating medium for 24Â h and then exposed to EVs for 48Â h (2Â ÃÂ 10<sup>7</sup> EVs/500Â Âµl). Cells were fixed and labelled with anti-G Protein-Coupled Receptor 17 (GPR17) and anti-MBP (TableÂ <xref ref-type="table" rid="Tab1">1</xref>) in Goat Serum Dilution Buffer (GSDB; 450Â mM NaCl, 20Â mM sodium phosphate buffer, pH 7.4, 15% goat serum, 0.3% Triton X-100), followed by secondary antibodies conjugated to Alexa Fluor 555 or Alexa Fluor 488 (1:200; Molecular Probes, Life Technologies). Differentiation towards mature oligodendrocytes was determined by counting MBP<sup>+</sup> cells over total DAPI+âcells in 35â45 fields per coverslip with ImageJ software. GPR17 staining was used to reveal immature oligodendrocytes, the most abundant oligodendrocyte population after 3Â day in differentiating medium.</p>
</sec>
<sec id="Sec21">
<title>OPC myelination assay</title>
<p id="Par46">OPC-DRG co-cultures were kept in 1Â Î¼gÂ ml<sup>â1</sup> TrkA-Fc for 5Â days and then exposed to EVs for 11Â days (fresh EVs, 2Â ÃÂ 10<sup>7</sup> EVs/500Â Âµl, were added at day in vitro (DIV5, DIV8 and DIV12). Cells were fixed at DIV16 with paraformaldehyde and labelled with anti-MBP and anti-high-molecular-weight neurofilaments (NF) antibodies (SMI31 and SMI32 in TableÂ <xref ref-type="table" rid="Tab1">1</xref>) in GSDB, followed by secondary antibodies conjugated to Alexa Fluor 555 or Alexa Fluor 488 (1:600; Molecular Probes, Life Technologies). Nuclei were labelled with DAPI. Coverslips were mounted with a fluorescent mounting medium (Dako, Milan, Italy). For the co-culture analysis, stacks of images of MBP- and SMI31- and SMI32-positive cells were taken under confocal microscope at 40Ã magnification (at 6 fields/coverslip) and the ZEISS LSM Image Browser was utilised to automate quantification of the myelination index. Images in the stack were merged at each level and pixels overlapping in the red and green fields above a predefined threshold intensity value were highlighted in white. The amount of myelin per axon (myelination index) was calculated as the ratio between the white pixel and the green pixel areas.</p>
</sec>
<sec id="Sec22">
<title>Western blot analysis</title>
<p id="Par47">OPCs were lysed with a buffer containing 1% sodium dodecyl sulphate (SDS), 10â¯mM HEPES, 2â¯mM EDTA pH 7.4. A modified version of the Laemmli buffer (20â¯mM Tris pH 6.8, 2â¯mM EDTA, 2% SDS, 10% glycerol, 2% Î²-mercaptoethanol, 0.01% bromophenol blue) was then added to a final 1Ã concentration and proteins were separated by electrophoresis, blotted on nitrocellulose membrane filters and probed using the using the primary antibodies reported in the TableÂ <xref ref-type="table" rid="Tab1">1</xref> and the HRP-conjugated secondary antibodies (goat anti-rat 1:1000, goat anti-rabbit 1:4000 and goat anti-mouse 1:2000; Sigma Aldrich, Milan, Italy). Photographic development was by chemiluminescence (ECL, GE Healthcare) according to the manufacturerâs instructions. Densitometric analysis of the protein bands was performed with ImageJ software. Band intensities were measured as integrated density volumes (IDV) and expressed as percentage of control lane values.</p>
</sec>
<sec id="Sec23">
<title>ELISA</title>
<p id="Par48">The concentration of IL-1a or C1q or TNF-Î± in microglial cells or EVs was quantified using a solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) kit following the manufacturerâs protocol (Rat IL-1a ELISA kit, Invitrogen Waltham, MA, USA, BMS627; Rat TNF-Î± ELISA kit, Invitrogen Waltham, MA, USA, BMS622, Rat C1q ELISA kit, Novus Biologicals Centennial, CO, USA, NBP2-74988). IL-1a or C1q or TNF-Î± content in the cells was determined after cell lysis with RIPA Buffer (Sigma Aldrich, Milan, Italy), whereas inside EVs after detergent permeabilization with 0.6% Triton X-100 (Sigma Aldrich, Milan, Italy) in the presence of protease inhibitors (1:1000, Sigma Aldrich, Milan, Italy). Sample absorbance was measured with a spectrophotometric system (1420 Multilabel Counter Victor 2; Wallac) at 450Â nm at 10Â Hz. The amount of IL-1a, C1q or TNF-Î± in EVs was estimated on the basis of a standard curve in the presence 0.6% Triton X-100.</p>
</sec>
<sec id="Sec24">
<title>Cryo-electron microscopy</title>
<p id="Par49">Cryo-EM allows imaging of samples without the addition of any heavy metals or fixatives, which might cause artefacts, with the drawback of yielding a lower contrast. The sample is frozen so rapidly that the water vitrifies forming no ordered crystals, and the native structure of the sample is preserved [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Freshly prepared vesicles resuspended in saline were plunge frozen in liquid propane using a Vitrobot Mark IV (ThermoFisher Scientific, Oregon, USA).</p>
</sec>
<sec id="Sec25">
<title>Drugs and reagents</title>
<p id="Par50">S-FTY720-Vinylphosphonate (kind gift from Prof. Robert Bittman) was dissolved in fatty acid-free bovine serum albumin (1Â mM in PBS). S1P (Enzo Biochem. Inc, Farmingdale, NY, USA) was dissolved in fatty acid-free bovine serum albumin (4Â mgÂ ml<sup>â1</sup> in distilled water). Stock solutions were diluted in fresh KrebsâRinger solution.</p>
</sec>
<sec id="Sec26">
<title>Statistical analysis</title>
<p id="Par51">All data are presented as meanâÂ±âSEM from the indicated number of experiments âNâ. Statistical analysis was performed using SigmaStat 3.5 software (SigmaStat software, San Jose, CA, USA). After testing data for normal distribution, the appropriate statistical test was used and the overall <italic>p</italic> value indicated in the figure legends. Group differences were considered significant when <italic>p</italic> wasâ&lt;â0.05, indicated by an asterisk; those at <italic>p</italic> wasâ&lt;â0.01 are indicated by double asterisks; those at <italic>p</italic>â&lt;â0.001 are indicated by triple asterisks. For the Raman spectra, Principal Component Analysis and Linear Discriminant Analysis (PCA-LDA) were performed by means of Origin2018 (OriginLab, Northampton, MA, USA). To test the sensitivity, specificity and accuracy of the classification model to distinguish the EV phenotype by the overall biochemical composition, leave-one-out cross-validation was used.</p>
</sec>
</sec>
<sec id="Sec27">
<title>Results</title>
<sec id="Sec28">
<title>EVs bud at the surface of microglia infiltrating the myelin lesion</title>
<p id="Par52">Injection of the detergent lysolecithin into the mouse corpus callosum (CC) causes a demyelinating injury within 4Â days which spontaneously recovers over time, offering a robust approach to study remyelination [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. In this model, infiltration and activation of macrophage/microglia were shown to be important for OPC migration and successful differentiation into myelin-forming cells [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR64">64</xref>].</p>
<p id="Par53">Ten days after the lesion (dpl), through high-resolution EM analysis, we found cells with the ultrastructural features of microglia (Fig.Â <xref ref-type="fig" rid="Fig1">1</xref>a) along with astrocytes and oligodendrocytes (Fig.Â <xref ref-type="fig" rid="Fig1">1</xref>b) at the lesion site. Importantly, microglia exhibited condensed, electron-dense cytoplasm and nucleoplasm, resembling âdarkâ microglia, a recently described phenotype of reactive cells [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], characterized by pronounced chromatin remodelling, which is indicative of altered gene expression. Although the narrow conformation of the extracellular space commonly constrains EV visualisation, we observed a dark microglial cell infiltrating the lesion, with several blebs at the cell surface and surrounded by putative membrane vesicles in the pericellular space (Fig.Â <xref ref-type="fig" rid="Fig1">1</xref>c), suggesting intense EV production. This evidence prompted us to investigate the role of EVs in the interplay between reactive microglia and OPCs at lesion sites. Inhibiting endogenous EV production without interfering with the remyelination process is challenging, given that most effective pharmacological or genetic inhibitors of EV biogenesis interfere with sphingolipid metabolism [<xref ref-type="bibr" rid="CR94">94</xref>]. We, therefore, analysed the action of exogenous EVs produced in vitro by polarised microglia.<fig id="Fig1"><label>Fig.Â 1</label><caption><p>Microglia infiltrating the myelin lesion release EVs. EM images of the CC showing dark cells resembling microglia (<bold>a</bold>), oligodendrocytes (<bold>b</bold>) and astrocytes (<bold>b</bold>) infiltrating demyelinated lesion at 10Â dpl. High magnification inserts in <bold>c</bold> show examples of EVs budding from the surface of dark microglia (scale bars 2Â Î¼m)</p></caption><graphic id="MO1" xlink:href="401_2019_2049_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec29">
<title>Distinct phenotypic signatures of EVs released by either pro-inflammatory or pro-regenerative microglia</title>
<p id="Par54">Primary rat microglia were maintained in the absence of stimuli (NS), under inflammatory (Th1 cytokine cocktail) or pro-regenerative (IL-4) conditions for 48Â h. They were also co-cultured with MSCs in transwell system in the presence of inflammatory cytokines (Fig.Â <xref ref-type="fig" rid="Fig2">2</xref>a) to drive pro-regenerative functions [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. Gene expression analysis revealed distinct patterns of phenotypic marker expression in the four conditions. Despite common upregulation of pro-regenerative arginase 1 (Arg1) in MSC-treated and IL-4-treated microglia, the former ones maintained pro-inflammatory traits (elevated IL-1a, C1q, IL-1Î² and iNOS) and selectively upregulated a few genes, including Suppressor of cytokine signaling 3 (Socs-3), a gene involved in negative regulation of cytokines and Choline Phosphotransferase 1 (Chpt1), an enzyme involved in phosphatidylcholine synthesis (Fig.Â <xref ref-type="fig" rid="Fig2">2</xref>b).<fig id="Fig2"><label>Fig.Â 2</label><caption><p>Production and characterization of EVs released by microglia with different activation states. <bold>a</bold> Scheme of microglia polarisation in vitro. <bold>b</bold> Gene expression of inflammatory markers (IL-1a, C1q, TNF-Î±, IL-1Î² and iNOS), pro-regenerative markers (Arg1 and Socs-3) and the metabolic gene Chpt1 in unstimulated microglia (NS-MG), IL-4-treated microglia (IL-4-MG) or microglia stimulated with inflammatory cytokines in the absence (i-MG) or in the presence of MSCs (MSC-MG) [number of independent experiments (<italic>n</italic>)â=â7â11/group; KruskalâWallis test with Dunnâs multiple comparison *<italic>p</italic>â&lt;â0.05, **<italic>p</italic>â&lt;â0.01, ***<italic>p</italic>â&lt;â0.001. <bold>c</bold> Representative cryo-EM images of the heterogeneous population of microglial EVs in the 100Â kÂ g pellet. <bold>d</bold> Size profile of EVs pelleted from 1Â ÃÂ 10<sup>6</sup> microglia, re-suspended in 100Â Î¼l of 0.1Â Âµm-filtered PBS and analysed using NTA (top). Histograms show production of EVs from NS or polarised microglia during 30Â min stimulation with 1Â mM ATP (bottom) (<italic>n</italic>â=â4; one way ANOVA <italic>p</italic>â=â0.2898 with Tukeyâs multiple comparisons test]. <bold>e</bold> Mean Raman spectra obtained using 532Â nm laser line from EVs of NS or polarized microglia. All spectra were baseline corrected, aligned and normalised before averaging. <bold>f</bold> Multivariate statistical analysis performed on the Raman spectra (<italic>n</italic>ââ¥â30 per sample). The scatter plot represents the values obtained for the Canonical Variable 1 and Canonical Variable 2 after LDA. In the classification model, spectra from EVs were grouped based on the cell of origin to test RS ability to discriminate the molecular composition of EVs from different microglial phenotypes. The first 10 PC scores calculated by means of PCA were used for the LDA. Each dot represents a single spectrum</p></caption><graphic id="MO2" xlink:href="401_2019_2049_Fig2_HTML"></graphic></fig></p>
<p id="Par55">Non-stimulated (NS) microglia and polarised cells were exposed to ATP for 30Â min to promote EV release, and EVs were isolated by ultracentrifugation at 100Â kg after pre-clearing of cell supernatants from cells and debris [<xref ref-type="bibr" rid="CR34">34</xref>]. Cryo-electron microscopy (cryo-EM) analysis revealed that most EVs from NS microglia consisted of a single lipid bilayer (Fig.Â <xref ref-type="fig" rid="Fig2">2</xref>c, câ³, câ´; 88%) and were rounded in shape (Fig.Â <xref ref-type="fig" rid="Fig2">2</xref>câcâ³; 66%), but were very heterogeneous in size, ranging from 15 to 1070Â nm in diameter (mean diameter 81.14âÂ±â9.11Â nm). A subpopulation of EVs contained one or more vesicles in their lumen (10%; Fig.Â <xref ref-type="fig" rid="Fig2">2</xref>câ²), or were coated on their surface (Fig.Â <xref ref-type="fig" rid="Fig2">2</xref>câ³; 15%), likely due to the presence of transmembrane or membrane-associated proteins. According to our previous evidence [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR95">95</xref>], cryo-EM excluded contamination with apoptotic bodies or intracellular organelles derived from damaged cells. Nanosight Tracking Analysis showed no major changes in total EV production from reactive microglia compared to NS cells (Fig.Â <xref ref-type="fig" rid="Fig2">2</xref>d). Conversely, clear differences in the molecular composition of EVs derived from polarised microglia were revealed by Raman spectroscopy (Fig.Â <xref ref-type="fig" rid="Fig2">2</xref>e), a sensitive optical technique already proven to provide information on the chemical content of EVs [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. Beside the characteristic bands of proteins and nucleic acids (proteins: Amide I 1600â1690Â cm<sup>â1</sup>, Amide III 1200â1300Â cm<sup>â1</sup>; nucleic acids: 720â820Â cm<sup>â1</sup>), main differences were identified in the spectral intervals that can be attributed to lipid components (mainly 2700â3200Â cm<sup>â1</sup>). In particular, EVs derived from non-stimulated and polarised microglia showed differences in the relative intensities of peaks attributable to cholesterol and cholesterol ester (700; 1127; 1440Â cm<sup>â1</sup>) and in peaks corresponding to the CH<sub>2</sub> deformations (around 1300Â cm<sup>â1</sup>) and CH, CH<sub>2</sub>, and CH<sub>3</sub> bonds (in the spectral range 2600â3200Â cm<sup>â1</sup>), which are known to be related to lipids [<xref ref-type="bibr" rid="CR43">43</xref>]. Despite such similarities, significant differences among IL4-EVs and MSC-EVs spectra were highlighted by linear discrimination analysis, suggesting that the two types of EVs carry distinct cargoes beyond common molecules, thus reflecting the distinct phenotypes of donor cells. The classification model PCA-LDA demonstrated that RS can distinguish the microglia phenotypes of the EV source with an overall accuracy of 91.7% and an error rate of 18.24% after cross-validation. The error rate was reduced to 10.16% when analysing spectra from broken EVs, busted by hypo-osmotic shock [<xref ref-type="bibr" rid="CR34">34</xref>] and re-pelleted to remove soluble components supporting the major contribution of membrane components in the spectral differences between the EV subtypes (Suppl. FigureÂ 1, Online Resource).</p>
</sec>
<sec id="Sec30">
<title>Microglia-derived EVs display a dual action on the oligodendroglial response to focal demyelinating lesions</title>
<p id="Par56">We first examined the action of EVs produced by inflammatory microglia (i-EVs) and pro-regenerative cells (IL4-EVs and MSC-EVs) on the early response to demyelination (3 dpl), during the phase of OPC recruitment [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. EVs produced by 1.5 million cells (~â2â3Â ÃÂ 10<sup>8</sup>) were delivered to focal myelin lesion via preâfilled Alzet mini-pumps for 4Â days (at 2Â ÃÂ 10<sup>6</sup> EVsÂ h<sup>â1</sup>). EVs were still present in the mini-pumps 3Â days after re-suspension, albeit the concentration was reduced byâ~â30%, as measured by Nanosight Tracking Analysis (EV concentrationâ=â2.80âÃâ10<sup>8</sup>âÂ±â0.19 at day 0; 2.60âÃâ10<sup>8</sup>âÂ±â0.13 at day 1; 1.90âÃâ10<sup>8</sup>âÂ±â0.08 at day 3). Mice received BrdU twice (2Â h apart), at 4Â dpl, to monitor cell proliferation and the tissue was analysed at the end of the treatment (7Â dpl) (Fig.Â <xref ref-type="fig" rid="Fig3">3</xref>a).<fig id="Fig3"><label>Fig.Â 3</label><caption><p>Action of EVs on early response to EVs. <bold>a</bold> Experimental design of EV delivery to LPC-treated mice during the phase of OPC recruitment. Histograms show the density of total proliferating cells (<bold>b</bold>) [number of animals (<italic>N</italic>)â=â3â5/group; one-way ANOVA main effect of treatment <italic>p</italic>â=â0.0021 with HolmâSidakâs multiple comparisons test vs Saline] and the percentage of BrdU<sup>+</sup> proliferating OPCs (<bold>c</bold>) (<italic>N</italic>â=â3â5/group; one way ANOVA <italic>p</italic>â=â0.0165 with HolmâSidakâs multiple comparisons test vs Saline] in saline, i-EVs- IL4-EVs- or MSC-EVs-injected lesions. <bold>d</bold> Representative images of Saline, i-EVs, IL4-EVs or MSC-EVs-injected lesions (area delimited by dotted line) immunostained against Sox10 (red) (scale bars of images and insets, 50Â Î¼m). Low magnification inserts show Sox10/DAPI double staining to visualise nuclei. <bold>e</bold> Corresponding density of Sox10<sup>+</sup> cells (histograms) (<italic>N</italic>â=â3â5/group; one way ANOVA <italic>p</italic>â=â0.0013 with Holm-Sidakâs multiple comparisons test vs Saline) and percentage of immature (NG2<sup>+</sup> Sox10<sup>+</sup>) oligodendrocytes (red line) (<italic>N</italic>â=â3â5/group; one way ANOVA <italic>p</italic>â=â0.0074 with HolmâSidakâs multiple comparisons test vs Saline). <bold>fâh</bold> Representative images of saline, i-EVs, IL4-EVs or MSC-EVs-injected lesions (area delimited by dotted line) immunostained against MBP (green) and DAPI (blue) (<bold>f</bold>) or against NG2 (green), Sox10 (red) and DAPI (blue) (<bold>h</bold>) (scale bars 50Â Î¼m). <bold>g</bold>, <bold>i</bold> Histograms show the percentage of the lesioned area immunoreactive for MBP (<bold>g</bold>) (<italic>N</italic>â=â3â7/group; one way ANOVA <italic>p</italic>â=â0.0001 with HolmâSidakâs multiple comparisons test vs Saline) or NG2 (<bold>i</bold>) (<italic>N</italic>â=â3â4/group; one way ANOVA <italic>p</italic>â=â0.0173 with HolmâSidakâs multiple comparisons test vs Saline) in saline-injected mice and mice that received different types of EVs</p></caption><graphic id="MO3" xlink:href="401_2019_2049_Fig3_HTML"></graphic></fig></p>
<p id="Par57">Quantification of BrdU<sup>+</sup> cells showed that all EV types significantly increased cell proliferation in the lesion area compared to saline-injected controls (Fig.Â <xref ref-type="fig" rid="Fig3">3</xref>b). However, we found almost no impact of EVs on the proliferation of Olig2<sup>+</sup> oligodendroglial cells (Fig.Â <xref ref-type="fig" rid="Fig3">3</xref>c), indicating that other brain cells proliferate in response to EVs. While not increasing oligodendrocyte proliferation, both IL4-EVs and MSC-EVs increased the density of oligodendroglial cells positive for the transcription factors Sox10 in the lesion area, suggesting enhanced migration of OPCs to the lesion site (Fig.Â <xref ref-type="fig" rid="Fig3">3</xref>d, e). Staining for myelin protein MBP showed that both IL4-EVs and MSC-EVs promoted the full differentiation of oligodendrocytes, as shown by increased MBP<sup>+</sup> labelling in the lesioned area (Fig.Â <xref ref-type="fig" rid="Fig3">3</xref>f, g). This maturation effect was accompanied by a decrease in immature NG2â+âOPCs (NG2<sup>+</sup>/Sox10<sup>+</sup> cells) (Fig.Â <xref ref-type="fig" rid="Fig3">3</xref>e) and an increase in density of oligodendrocytes undergoing differentiation (NG2<sup>â</sup>Sox10<sup>+</sup> cell density: saline, 721.3âÂ±â88.64; i-EVs, 562.0âÂ±â40.31; IL4-EVs, 755.1âÂ±â82.13; MSC-EVs, 1080âÂ±â98.97; one-way ANOVA main effect of treatment <italic>p</italic>â=â0.0114 with Holm-Sidakâs multiple comparisons test) upon MSC-EVs delivery. By contrast, the fraction of MBP staining in the lesioned area decreased upon i-EV infusion (Fig.Â <xref ref-type="fig" rid="Fig3">3</xref>f, g) while the tissue exhibited a significant increase in NG2 staining (Fig.Â <xref ref-type="fig" rid="Fig3">3</xref>h, i). Accordingly, the percentage of NG2<sup>+</sup>/Sox10<sup>+</sup> early progenitors increased in comparison to controls (Fig.Â <xref ref-type="fig" rid="Fig3">3</xref>e).</p>
<p id="Par58">Overall, these data indicate that prolonged delivery of EVs produced by beneficial microglia, especially MSC-treated microglia, promotes the accumulation of oligodendrocytes at the lesion site and enhances remyelination, whereas i-EVs injection inhibits OPC maturation.</p>
<p id="Par59">To further assess the impact of EVs on OPC differentiation, MSC-EVs and i-EVs (7âÃâ10<sup>7</sup> EVs, corresponding to about one third of EVs delivered over 4Â days via the minipump) were delivered to LPC-treated mice by a single injection at 7Â dpl, when OPCs become post-mitotic and progress toward differentiation into myelin-sheath forming oligodendrocytes [<xref ref-type="bibr" rid="CR64">64</xref>]. The remyelination process was analysed at 10Â dpl in both young (2.5â4Â months old) and aged (8â12Â months old) mice (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>a), in which remyelination occurs more slowly [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR82">82</xref>â<xref ref-type="bibr" rid="CR84">84</xref>]. MRI analysis showed that this time-window is optimal to study remyelination in our experimental setting. Indeed, at 5â6 dpl, before EV treatment, hyper-intense signal on T2-weighted MR images indicated clear myelin lesions in almost the entire CC, whereas at 10Â dpl CC signal returned hypointense almost similar to healthy controls, suggesting fast recovery (Suppl. FigureÂ 2, Online Resource). Remyelination of CC was also observed by diffusion tensor imaging (DTI), showing considerably increased diffusivity perpendicular to white matter fibres at 5Â dpl, and return to normal values at 10Â dpl (Suppl. FigureÂ 2, Online Resource).<fig id="Fig4"><label>Fig.Â 4</label><caption><p>Action of EVs on myelin deposition in acute LPC-mediated focal demyelination. <bold>a</bold> Experimental protocol of EV delivery to LPC-treated mice during the phase of OPC differentiation. <bold>b</bold> Histograms show percentage of immature (Sox10<sup>+</sup>NG2<sup>+</sup>) and differentiated cells (Sox10<sup>+</sup>NG2<sup>â</sup>), oligodendrocytes in saline-injected mice and mice that received i-EVs or MSC-EVs (<italic>N</italic>â=â3â4/group; KruskalâWallis test <italic>p</italic>â=â0.0129 with Dunnâs multiple comparisons test vs Saline). Representative images of saline, i-EVs or MSC-EVs-injected lesions (area delimited by dotted line), immunostained against MBP (green, <bold>c</bold>), NG2 (green, <bold>e</bold>), or CC1 (yellow, <bold>g</bold>) (scale bars 50Â Î¼m). Histograms show the percentage of the lesioned area immunoreactive for MBP (<bold>d</bold>) (<italic>N</italic>â=â3â4/group; one-way ANOVA <italic>p</italic>â&lt;â0.0001 with HolmâSidakâs multiple comparisons test), NG2 (<bold>f</bold>) (<italic>N</italic>â=â4/group; one-way ANOVA <italic>pâ</italic>&lt;â0.0001 with HolmâSidakâs multiple comparisons test) or the density of mature oligodendrocytes (CC1) (<bold>h</bold>) (<italic>N</italic>â=â3/group; one-way ANOVA <italic>p</italic>â&lt;â0.0001 with HolmâSidakâs multiple comparisons test. <bold>i</bold> Representative electron micrographs of CC in saline-injected mice and mice that received i-EVs or MSC-EVs (scale bars of images, 1Â Î¼m; original magnification 25,000). <bold>j</bold> Histograms show the percentage of unmyelinated/myelinated fibres (<italic>N</italic>â=â3/group; one-way ANOVA <italic>p</italic>â=â0.039 with Dunnâs multiple comparison test). <bold>k</bold> Myelin thickness can be quantified by the <italic>G</italic>-ratio, defined as the ratio between the inner (axonal, <bold>d</bold>, white) and outer (overlying myelin, <bold>d</bold>, yellow) diameters of myelinated axons. Scale bar of image, 1.5Â Î¼m. <bold>l</bold> Histograms show quantifications of the <italic>G</italic>-ratio (<italic>N</italic>â=â3/group; KruskalâWallis test <italic>p</italic>â&lt;â0.0001 with Dunnâs multiple comparisons test). <bold>m</bold> Histograms show myelin sheath thickness (<italic>N</italic>â=â3/group; KruskalâWallis test <italic>p</italic>â&lt;â0.0001 with Dunnâs multiple comparisons test). Each dot represents an individual value. <bold>n</bold> Scatter plots of <italic>G</italic>-ratio against axon diameter. The <italic>G</italic>-ratio of each measured myelinated fibre is indicated by a single circle (<italic>n</italic>â=â160 saline, <italic>n</italic>â=â167 MSC-EVs, <italic>n</italic>â=â169 i-EVs). Correlation between axon diameter (x1) and <italic>G</italic>-ratio (y1) is expressed by the correlation coefficient (<italic>r</italic>) of the linear regression curve (saline: <italic>r</italic>â=â0.503, i-EVs: <italic>r</italic>â=â0.518; MSC-EVs: <italic>r</italic>â=â0.448)</p></caption><graphic id="MO4" xlink:href="401_2019_2049_Fig4_HTML"></graphic></fig></p>
<p id="Par60">The presence of EVs at the lesion site was verified in mice injected with GFP-labelled EVs produced by GFP-expressing microglia. Twenty minutes after a single injection, GFP-EVs were localised within the lesion evidenced by DAPI staining (Suppl. FigureÂ 3aâdâ², Online Resource). Immunolabelling for the lineage markers Iba1, S100Î² or NG2 and 3D reconstruction by Imaris showed GFP-EVs inside microglia/macrophages (Suppl Fig.Â 3eâeâ²â´, Online Resource), astrocytes (Suppl Fig.Â 3fâfâ³, Online Resource) or NG2<sup>+</sup> cells (Suppl Fig.Â 3Â gâgâ´, Online Resource). 60Â min after injection, GFP-EVs were no longer visible in proximity or away from the injury (not shown). Despite being injected in a single-pulse and in lower amounts compared to the prolonged treatment, both i-EVs and MSC-EVs had a strong impact on oligodendrocytes during the phase of OPC differentiation. In aged mice, i-EVs produced a significant decrease in MBP staining (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>c, d) with no changes in the fraction of NG2 staining in the lesioned area (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>e, f) and in the percentage of NG2<sup>+</sup> early progenitors (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>b). Compared to saline and i-EV injected animals, mice receiving MSC-EVs showed enhanced MBP staining (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>c, d) and decreased NG2 labelling (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>e, f), consistent with OPC differentiation into myelin-sheath forming oligodendrocytes. These results were corroborated by the increase in the density of oligodendrocytes positive for CC1, a myelinating oligodendrocyte marker that stains the cell body [<xref ref-type="bibr" rid="CR6">6</xref>] (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>g, h), and by the decrease in the percentage of NG2<sup>+</sup>/Sox10<sup>+</sup> early progenitors at lesion site (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>b).</p>
<p id="Par61">In young mice, i-EVs also exerted an inhibitory action on OPC maturation, as indicated by decreased MBP staining at the lesion site (Fig.Â <xref ref-type="fig" rid="Fig5">5</xref>a, b), while the effect of MSC-EVs was less evident. Compared to i-EVs, MSC-EVs significantly increased MBP immunoreactivity (Fig.Â <xref ref-type="fig" rid="Fig5">5</xref>a, b), decreased NG2 staining (Fig.Â <xref ref-type="fig" rid="Fig5">5</xref>c, d) and enhanced the density of CC1<sup>+</sup> differentiated oligodendrocytes (Fig.Â <xref ref-type="fig" rid="Fig5">5</xref>e, f), but failed to increase remyelination over control levels (Fig.Â <xref ref-type="fig" rid="Fig5">5</xref>a, b, e, f).<fig id="Fig5"><label>Fig.Â 5</label><caption><p>Action of microglia-derived EVs on OPC differentiation at myelin lesion in young mice. Representative images of saline, i-EVs and MSC-EVs-injected lesions (area delimited by dotted line), immunostained against MBP (green, <bold>a</bold>), NG2 (green, <bold>c</bold>), or CC1 (yellow, <bold>e</bold>) (scale bars 50Â Î¼m). Low magnification inserts show double labelling for DAPI. Histograms show the percentage of the lesioned area immunoreactive for MBP (<bold>b</bold>), NG2 (<bold>d</bold>) or CC1 (<bold>f</bold>) at 7Â dpl in saline-injected mice and mice injected with i-EVs or MSC-EVs [number of animals (<italic>N</italic>)â=â3â5/group, one-way ANOVA with HolmâSidakâs multiple comparison: MBP, <italic>p</italic>â=â0.0012; NG2, <italic>p</italic>â&lt;â0.0001; CC1, <italic>p</italic>â=â0.0090)</p></caption><graphic id="MO5" xlink:href="401_2019_2049_Fig5_HTML"></graphic></fig></p>
<p id="Par62">Altogether, these data indicate that, while inflammatory microglia inhibit OPC differentiation and remyelination through secretion of i-EVs, MSC-treated microglia release EVs which favor recruitment and transition of NG2 cells into mature myelinating oligodendrocytes at the lesion site.</p>
</sec>
<sec id="Sec31">
<title>EVs from different sources induce qualitatively and quantitatively different myelin ultrastuctural features</title>
<p id="Par63">For a more detailed definition of myelin ultrastructure, we evaluated the remyelination process by EM analysis at 10Â dpl in the CC of aged lesioned mice that received either i-EVs, or MSC-EVs or saline by a single injection. i-EVs-injected mice displayed a higher G ratio (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>kâm) and thinner myelin (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>l) compared to saline-injected mice, confirming that i-EVs hamper remyelination. By contrast, mice injected with MSC-EVs exhibited a higher percentage of myelinated fibres (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>i, j), lower G ratio (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>kâm) and higher myelin sheath thickness (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>l) compared to saline control samples and i-EVs-injected mice, consistent with a promoting action of MSC-EVs on myelin repair.</p>
</sec>
<sec id="Sec32">
<title>Strong impact of EVs on OPC migration: the role of sphingosine-1-phosphate</title>
<p id="Par64">To investigate the molecular mechanisms underlying harmful and protective action of microglia-derived EVs, we set up primary OPC cultures, a powerful system with easy access for EVs, which allows to dissect their direct effects. All in vitro experiments were performed by exposing OPCs to EVs produced by twice as many microglial cells, in order to keep conditions close to physiology. To further explore how the differential activation state of microglia influences EV action, NS-EVs were included in the analyses.</p>
<p id="Par65">First, we explored whether EVs have the capacity to influence OPC proliferation and/or migration, two mechanisms involved in oligodendrocyte recruitment into focal myelin lesion. The impact of EVs on proliferation was assessed by exposing cultured OPCs to the different types of EVs for 24Â h in the presence of the proliferative marker EdU. Quantitative analysis of EdU<sup>+</sup> OPCs showed that i-EVs reduce OPC proliferation, albeit with no statistical significance, while EVs produced by pro-regenerative microglia (either IL4-EVs or MSC-EVs) significantly increased OPC proliferation compared to i-EVs-treated, but not to NS-EVs or untreated (control) OPCs (Fig.Â <xref ref-type="fig" rid="Fig6">6</xref>a, b). In agreement with in vivo observations, these data show very mild effects of EVs on OPC proliferation. By contrast, the impact of EVs on OPC migration was much stronger. Using a classical transwell-based migration assay, we found that all types of EVs significantly enhance the transit of OPCs through the transwell filter, regardless of the activation state of parent microglia (Fig.Â <xref ref-type="fig" rid="Fig6">6</xref>c).<fig id="Fig6"><label>Fig.Â 6</label><caption><p>EV impact on OPC migration, differentiation and myelination. <bold>a</bold>, <bold>b</bold> Fluorescence images of cultured OPCs incubated with EdU (red), fixed and stained for NG2 (green) and DAPI (blue) after 24Â h exposure to i-EVs or MSC-EVs (scale bars 50Â Âµm). The histograms in <bold>b</bold> show the percentage of EdU<sup>+</sup> OPCs in cultures exposed or not to different EV types. Data have been normalized to control [number of experiments (<italic>n</italic>)â=â5â8/group; KruskalâWallis test <italic>p</italic>â&lt;â0.0001 with Dunnâs multiple comparisons test]. <bold>c</bold> Histograms show the percentage of OPCs migrated through the filter of the Boyden chamber in control conditions and following addition of different types of EVs. Data have been normalized to control (<italic>n</italic>â=â3; one-way ANOVA <italic>p</italic>â=â0.0054 with HolmâSidakâs multiple comparisons test vs control). <bold>d</bold> Percentage of migrated OPCs in response to S1P or IL-4-EVs in the presence or in the absence of the S1P receptor antagonist S-FTY720-Vinylphosphonate (<italic>n</italic>â=â3; KruskalâWallis test <italic>p</italic>â&lt;â0.0001 with Dunnâs multiple comparisons test). <bold>e</bold> Representative images of OPCs maintained in control conditions or exposed to different types of EVs for 2Â days, fixed and stained for MBP (red), GPR17 (green) and DAPI (blue) (scale bars 50Â Âµm). <bold>f</bold> Corresponding quantification of MBP<sup>+</sup> OPCs. Data have been normalized to control (<italic>n</italic>â=â5â8/group, KruskalâWallis test <italic>p</italic>â&lt;â0.0001 with Dunnâs multiple comparisons test vs control). <bold>g</bold> Western blot of control OPCs and IL4-EVs-treated OPCs for the indicated markers of OPC differentiation. Tubulin has been used as loading control. Relative quantification of the band density is shown on the right (<italic>n</italic>â=â3; CNPase: unpaired <italic>t</italic> test <italic>p</italic>â=â0.0033; MBP: unpaired <italic>t</italic> test <italic>p</italic>â=â0.0018; GST-pi: unpaired <italic>t</italic> test <italic>p</italic>â&lt;â0.0001; GPR17: unpaired <italic>t</italic> test <italic>p</italic>â=â0.0224). <bold>h</bold> Representative images of OPC-DRG co-cultures maintained in control conditions or exposed to i-EVs, IL4-EVs or MSC-EVs for 11Â days, fixed and stained for MBP (red) and neurofilament (NF, green) (scale bars 20Â Âµm). <bold>e</bold> Myelination index (MBP staining/NF staining) under different experimental conditions (<italic>n</italic>â=â3; KruskalâWallis test <italic>p</italic>â&lt;â0.0001 with Dunnâs multiple comparisons test vs control)</p></caption><graphic id="MO6" xlink:href="401_2019_2049_Fig6_HTML"></graphic></fig></p>
<p id="Par66">EVs contain components of the sphingolipid pathway, which play a key role in biogenesis and biological action of EVs [<xref ref-type="bibr" rid="CR94">94</xref>]. Among them, sphingosine-1-phosphate (S1P) is a known chemoattractant agent [<xref ref-type="bibr" rid="CR49">49</xref>], which may be involved in OPC migration. To test this hypothesis, we pulse-labelled microglia with [<sup>3</sup>H]sphingosine ([<sup>3</sup>H]sph) under conditions of metabolic equilibrium and measured the content of [<sup>3</sup>H]sphingolipids in EVs and parental cells. We found detectable levels of [<sup>3</sup>H]S1P along with more abundant sphingolipids (sphingomyelin, lactosylceramide and monosialodihexosylganglioside (GM3) in EVs produced by NS microglia, but S1P was not enriched in EVs compared to donor cells (TableÂ <xref ref-type="table" rid="Tab3">3</xref>). We next monitored OPC migration in the presence of the pan S1P receptor antagonist S-FTY720-Vinylphosphonate (100Â nM) [<xref ref-type="bibr" rid="CR92">92</xref>] and found that the drug completely inhibited the capacity of EVs to attract OPCs (Fig.Â <xref ref-type="fig" rid="Fig6">6</xref>d).<table-wrap id="Tab3"><label>TableÂ 3</label><caption><p>Sphingolipid content in EVs and parental microglia</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Sphingolipid species</th><th align="left">% in cells</th><th align="left">% in EVs</th><th align="left">EVs/cell fold increase</th></tr></thead><tbody><tr><td align="left">[<sup>3</sup>H]Sphingomyelin</td><td align="char" char="Â±">27.55âÂ±â2.4</td><td align="char" char="Â±">33.88âÂ±â3.4</td><td align="char" char=".">1.2</td></tr><tr><td align="left">[<sup>3</sup>H]Ceramide</td><td align="char" char="Â±">4.04âÂ±â0.4</td><td align="char" char="Â±">4.60âÂ±â0.4</td><td align="char" char=".">1.1</td></tr><tr><td align="left">[<sup>3</sup>H]Glucosylceramide</td><td align="char" char="Â±">5.97âÂ±â0.5</td><td align="char" char="Â±">4.41âÂ±â0.4</td><td align="char" char=".">0.7</td></tr><tr><td align="left">[<sup>3</sup>H]Lactosylceramide</td><td align="char" char="Â±">19.26âÂ±â1.8</td><td align="char" char="Â±">11.41âÂ±â1.4</td><td align="char" char=".">0.6</td></tr><tr><td align="left">[<sup>3</sup>H]Sphingosine</td><td align="char" char="Â±">3.78âÂ±â0.4</td><td align="char" char="Â±">4.31âÂ±â0.5</td><td align="char" char=".">1.1</td></tr><tr><td align="left">[<sup>3</sup>H]GM3</td><td align="char" char="Â±">10.4âÂ±â0.6</td><td align="char" char="Â±">8.94âÂ±â1.0</td><td align="char" char=".">0.8</td></tr><tr><td align="left">[<sup>3</sup>H]Sphingosine-1-phosphate</td><td align="char" char="Â±">1.17âÂ±â0.14</td><td align="char" char="Â±">0.95âÂ±â0.15</td><td align="char" char=".">0.8</td></tr></tbody></table></table-wrap></p>
<p id="Par67">Collectively, these results indicate that microglial EVs promote OPC migration and highlight a role for vesicular S1P as attractive guidance cue for OPCs.</p>
</sec>
<sec id="Sec33">
<title>In vitro, EVs derived from both inflammatory and pro-regenerative microglia promote OPC differentiation</title>
<p id="Par68">To define direct effects of EVs on OPC differentiation, cells were incubated with the different types of EVs for 48Â h, fixed and stained for MBP. Unexpectedly, immunofluorescence analysis revealed that i-EVs significantly enhanced the fraction of MBP<sup>+</sup> oligodendrocytes in a similar way to IL4-EVs and MSC-EVs, whereas NS-EVs did not influence OPC maturation (Fig.Â <xref ref-type="fig" rid="Fig6">6</xref>e, f). No significant changes in the fraction of MBP<sup>+</sup> cells were observed with half or double concentration of IL4-EVs, excluding the possibility that small variations in EV amount could have had a strong impact on OPC maturation (normalized MBP<sup>+</sup> OPC fraction: 1.53âÂ±â0.26 standard EV dose; 1.42âÂ±â0.22 half dose; 1.27âÂ±â0.36 double dose). Western blot analysis confirmed that IL4-EVs enhance the expression of MBP along with other markers of mature oligodendrocytes, i.e. 2â²,3â²-cyclic nucleotide-3â²-phosphodiesterase (CNPase) and glutathione S-transferase (GST)-pi while downregulating GPR17, a marker of immature oligodendrocytes (Fig.Â <xref ref-type="fig" rid="Fig6">6</xref>g).</p>
<p id="Par69">Direct action of EVs on myelin deposition was investigated in OPCs co-cultured with DRG neurons, a useful system to study myelination [<xref ref-type="bibr" rid="CR16">16</xref>]. OPCs were exposed to EVs for 11Â days (three treatments, every 3/4Â days), fixed and immunostained with axon- and myelin-specific markers, i.e. high-molecular-weight neurofilaments (NF) and MBP, respectively. Quantitative analysis of the linear MBP<sup>+</sup> segments extending along axons showed that both IL-4-EVs and MSC-EVs favoured myelin deposition (Fig.Â <xref ref-type="fig" rid="Fig6">6</xref>h, i). However, i-EVs also significantly enhanced myelination, albeit at a lower extent compared to pro-regenerative EVs. NS-EVs had no significant effect on myelination (not shown). Of note, MSC-EVs displayed higher capacity to promote myelin deposition compared to EVs released by MSCs (Suppl. FigureÂ 4a, Online Resource).</p>
<p id="Par70">Globally, these results show that i-EVs exhibit direct pro-differentiating action on cultured OPCs. Thus, the blockade of OPC maturation caused by i-EVs in vivo likely involves other brain cells, which may acquire harmful function in response to i-EVs.</p>
</sec>
<sec id="Sec34">
<title>Astrocytes mediate the harmful effects of i-EVs on OPCs</title>
<p id="Par71">Recent evidence indicates that microglia can transform astrocytes into A1 harmful cells, which inhibit OPC differentiation [<xref ref-type="bibr" rid="CR99">99</xref>]. To investigate the possible involvement of astrocytes in the detrimental action of i-EVs, we grew OPCs on top of astrocytes and maintained the co-culture in the presence or absence of i-EVs for 48Â h. Immunofluorescence staining for MBP revealed that, in the absence of microglial i-EVs, astrocytes accelerated OPC differentiation, as indicated by higher percentages of MBP/Olig-2 double-positive cells in astrocyte-OPC co-cultures compared to OPCs cultured alone (Fig.Â <xref ref-type="fig" rid="Fig7">7</xref>a, b). However, when exposed to i-EVs, astrocytes caused a strong inhibition of OPC maturation (Fig.Â <xref ref-type="fig" rid="Fig7">7</xref>a, b). Consistent with harmful astrocyte transformation, qPCR analysis showed that, in response to i-EVs, pure cultured astrocytes upregulated the A1 reactive markers serping-1 and Amigo 2 [<xref ref-type="bibr" rid="CR55">55</xref>] (Fig.Â <xref ref-type="fig" rid="Fig7">7</xref>c), whilst exhibiting unaltered expression for the A2 markers pentraxin-3 (PTX3), CD14 and Tm4sf1 (Fig.Â <xref ref-type="fig" rid="Fig7">7</xref>d). In contrast, the lipid extract of i-EVs potently induced A2 markers (Fig.Â <xref ref-type="fig" rid="Fig7">7</xref>d), and slightly increased serping-1 and Amigo 2 (Fig.Â <xref ref-type="fig" rid="Fig7">7</xref>c), suggesting a shift of astrocytes towards beneficial rather than harmful functions. This indicates that other i-EVs components (proteins and/or RNAs) are mostly responsible for harmful astrocyte transformation. A1 astrocyte conversion likely occurred also in vivo in LPC-treated mice that received i-EVs for 4Â days (Fig.Â <xref ref-type="fig" rid="Fig3">3</xref>a). Indeed, GFAP-positive astrocytes, present at myelin lesion, showed decreased PTX3 labelling and increased, albeit non significant, immunoreactivity for the A1 marker C3a compared to saline-injected mice (Fig.Â <xref ref-type="fig" rid="Fig7">7</xref>e, f) No major changes in A1 and A2 markers occurred at protein and mRNA levels in astrocytes exposed to MSC-EVs in vivo and in vitro (Fig.Â <xref ref-type="fig" rid="Fig7">7</xref>câf).<fig id="Fig7"><label>Fig.Â 7</label><caption><p>Astrocytes transform the pro-differentiating action of i-EVs to inhibitory activity. <bold>a</bold> Representative images of OPCs cultured alone or with astrocytes in the presence or in the absence of i-EVs immunostained for MBP (red), Olig2 (green) and GFAP (cyan) (scale bars 20Â Î¼m). <bold>b</bold> Corresponding quantifications of MBP<sup>+</sup> OPCs (<italic>n</italic>â=â2; one-way ANOVA <italic>p</italic>â&lt;â0.0001 with Tukeyâs multiple comparisons test). Representative qPCR analysis of A1 (<bold>c</bold>) and A2 (<bold>d</bold>) marker expression in unstimulated astrocytes (control), astrocytes exposed to i-EVs, the lipid fraction of i-EVs (lipids), MSC-EVs (left panels). Right panels show A1 and A2 marker expression in astrocytes exposed to i-EVs in the presence/absence of the TNF-a inhibitor etanercept (ETN).Three replicates/condition have been normalized to control (one-way ANOVA <italic>p</italic>â&lt;â0.0001 with HolmâSidakâs multiple comparisons test). <bold>e</bold> Representative images of saline, i-EVs, or MSC-EVs-injected lesions, immunostained against C3 or PTX3 (red) and Hoechst (blue) (scale bars 50Â Î¼m). High magnification inserts show astrocytes double stained for GFAP (green) and C3 or PTX3 (red). <bold>f</bold> Density of C3- and PTX3-positive astrocytes at saline, i-EVs-, i-EVsâ+âETN, or MSC-EVs-injected lesions (C3, number of sectionsâ=â5â10/group; KruskalâWallis test <italic>p</italic>â=â0.0298 with Dunnâs multiple comparisons test among Saline, i-EVs and i-EVsâ+âETN); (PTX3, number of sectionsâ=â5â10/group; KruskalâWallis test <italic>p</italic>â&lt;â0.0001 with Dunnâs multiple comparisons test). <bold>g</bold> ELISA quantification of IL-1a, C1q, and TNF-Î± in 1X10<sup>6</sup> inflammatory microglia (i-MG) and in MSC-treated microglia (MSC-MG) (<italic>n</italic>â=â3; IL-1a, MannâWhitney <italic>t</italic> test <italic>p</italic>â=â0.9000; C1q, unpaired t test <italic>p</italic>â=â0.5619; TNF-Î±, MannâWhitney <italic>t</italic> test <italic>p</italic>â=â0.0286)</p></caption><graphic id="MO7" xlink:href="401_2019_2049_Fig7_HTML"></graphic></fig></p>
<p id="Par72">Three microglial mediators have been shown to be both necessary and sufficient for A1 astrocyte conversion, i.e. IL-1a, C1q and TNFÎ±. Of them, TNFÎ± and IL1-a are mostly released by immune cells in EV-associated form [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR86">86</xref>], while both TNFÎ± and C1q were previously detected in microglia-derived EVs [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. To assess the involvement of IL-1a, C1q and TNFÎ± in A1 astrocyte transformation, cytokine profile of i-EVs was assessed with specific ELISA. Detectable amounts of IL-1a, C1q and TNFÎ± were found in i-EVs isolated from 15Â ÃÂ 10<sup>6</sup> microglial cells (IL1-aâ~â90Â pg; C1q contentâ~â78Â pg; TNF-Î± contentâ~â613Â pg), supporting their role in harmful astrocyte transformation. Among the three inflammatory mediators, only TNF-Î± was suppressed in parental microglia by MSC conditioning at both protein and mRNA levels, as determined by ELISA (Fig.Â <xref ref-type="fig" rid="Fig7">7</xref>g) and qPCR (Fig.Â <xref ref-type="fig" rid="Fig2">2</xref>b). We, therefore, measured the TNFÎ± content in i-EVs and MSC-EVs. i-EVs displayed about threefold higher levels of TNF-Î± compared to MSC-EVs (i-EVs TNF-Î± contentâ~â613Â pg; MSC-EVs TNF-Î± contentâ~â168Â pg), suggesting that the capacity of MSC-EVs to promote myelin repair may occur, at least in part, via TNF-Î± suppression. To assess TNF-Î± involvement in astrocyte activation, we pre-treated i-EVs with Etanercept (ETN, 200Â ngÂ ml<sup>â1</sup>), a TNF-Î± inhibitor, before co-exposing astrocytes to i-EVs and ETN. qPCR analysis showed that TNF-Î± inactivation prevented serping-1 upregulation and induced PTX3 expression in vitro, suggesting a shift of cultured astrocytes towards beneficial function (Fig.Â <xref ref-type="fig" rid="Fig7">7</xref>c, d). Immunolabelling for C3 in vivo revealed a significant decrease in the density of astrocytes positive for the A1 marker at lesions co-injected with i-EVs and ETN compared to i-EVs alone. However, PTX3 staining showed that the inhibitor caused by itself a decrease in the density of PTX3 positive astrocytes, being not able to prevent the decrease in PTX3<sup>+</sup> astrocytes induced by i-EVs (Fig.Â <xref ref-type="fig" rid="Fig7">7</xref>e, f). Taken together, these data indicate that TNF-Î± is essential for the astrocyte response, despite its inactivation is not sufficient to prevent harmful astrocyte transformation in vivo.</p>
</sec>
<sec id="Sec35">
<title>EVs binds to the OPC cell surface</title>
<p id="Par73">While mechanisms underlying astrocyte reaction to microglial EVs have been previously studied [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR95">95</xref>], how EVs influence OPC activity is completely unknown. We explored whether EVs physically interact with OPCs. We placed single EV in contact with cultured OPCs using optical tweezers and monitored EV-OPC dynamics using time lapse microscopy (Fig.Â <xref ref-type="fig" rid="Fig8">8</xref>a). We observed that about 70% of NS-EVs adhered to the OPC surface (17 out of 24), suggesting that, in principle, most EVs could influence OPC function.<fig id="Fig8"><label>Fig.Â 8</label><caption><p>EVs efficiently interact with OPCs. <bold>a</bold> Schematic representation of EV delivery to OPCs by optical tweezers. EVs are first trapped above the OPCs by the IR laser tweezers (left), then the stage is moved in plane (<italic>XY</italic>) and the objective/trap is moved axially (<italic>Z</italic>) to set the EVs in contact with the OPCs (middle). The trapping laser is switched off to check whether EV adheres to the neuron membrane (right). <bold>aâ²</bold> Sequence of phase-contrast images showing one example of EV driven to an OPC following the procedure described in <bold>a</bold> (scale bar 10Â Î¼m). <bold>b</bold>, <bold>c</bold> OPCs were maintained in control condition or exposed to intact EVs, broken EVs or the lipid extract of EVs for 2Â days, fixed and stained for MBP. Histograms show the percentage of mature MBP<sup>+</sup> oligodendrocytes in cultures exposed to broken EVs derived from IL-4 microglia (Brk IL4-EVs) or MSC-treated cells (Brk MSC-EVs) (<bold>b</bold>; <italic>n</italic>â=â3; KruskalâWallis test <italic>p</italic>â=â0.0049 with Dunnâs multiple comparisons test versus control), intact EVs or native lipids (lipids) extracted from IL4-EVs (<bold>c</bold>; one-way ANOVA <italic>p</italic>â=â0.0001 with Holm-Sidakâs multiple comparisons test). Data have been normalized to control. <bold>d</bold> Percentage of differentiated MBP<sup>+</sup> oligodendrocytes in cultures exposed for 2Â days to i-EVs alone or in combination with S-FTY720-Vinylphosphonate, FTY720-Vinylphosphonate alone or S1P. Data have been normalized to control (<italic>n</italic>â=â3; KruskalâWallis test <italic>p</italic>â=â0.0009 with Dunnâs multiple comparisons test versus control)</p></caption><graphic id="MO8" xlink:href="401_2019_2049_Fig8_HTML"></graphic></fig></p>
</sec>
<sec id="Sec36">
<title>The pro-differentiation activity of EVs depends on the lipid components of EVs</title>
<p id="Par74">To investigate whether direct effects of EVs were mediated by factor(s) present at the surface or in the lumen of EVs, IL-4-EVs or MSC-EVs were busted by hypo-osmotic shock [<xref ref-type="bibr" rid="CR34">34</xref>] and membrane fragments pelleted to remove soluble components were added to cultured OPCs. Broken EVs, depleted of their content, retained the capability to promote OPC maturation (Fig.Â <xref ref-type="fig" rid="Fig8">8</xref>d), revealing that surface component(s) of EVs were mainly driving this process. To distinguish between protein and lipid component(s), we exposed OPCs to the lipid fraction of IL4-EVs (Fig.Â <xref ref-type="fig" rid="Fig8">8</xref>e) or i-EVs (not shown). EV lipids enhanced OPC maturation even more efficiently than intact EVs (Fig.Â <xref ref-type="fig" rid="Fig8">8</xref>e), indicating that the pro-differentiating activity of EVs is mostly attributable to their lipid components. Finally, given that previous studies have shown that S1P and its analog FTY720-p promote OPC differentiation and myelin deposition [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR65">65</xref>],Â we asked whether vesicular S1P may be implicated in the pro-differentiating activity of the EVs. We treated OPCs with the S1P receptor antagonist S-FTY720-Vinylphosphonate and found no changes in EV-induced OPC differentiation to MBP<sup>+</sup> oligodendrocytes (Fig.Â <xref ref-type="fig" rid="Fig8">8</xref>f), thus ruling out a role of vesicular S1P in OPC maturation.</p>
</sec>
</sec>
<sec id="Sec37">
<title>Discussion</title>
<p id="Par75">Our study reveals a previously unrecognised role of EVs produced by microglia in the control of remyelination, the spontaneous process by which OPCs differentiate into myelin-forming cells, restore myelin sheaths to protect axons from degeneration and allow fast signal transmission [<xref ref-type="bibr" rid="CR24">24</xref>]. Specifically, we show that exogenous EVs from differentially conditioned microglia exert opposite effects on remyelination, with either pro-regenerative or detrimental actions, depending on the type of conditioning stimulus. Importantly, our study also unveils an unprecedented role for astrocytes in mediating the detrimental effects of EVs from pro-inflammatory microglia. Finally, it gives a first identification of the distinct molecular components of EVs involved in astrocyte detrimental transition as well as in promotion of OPC migration and/or differentiation, thus unveiling new targets for modulation of myelin repair.</p>
<sec id="Sec38">
<title>EVs mediate microglial action on oligodendrocytes</title>
<p id="Par76">Previous evidence had shown that microglial phenotype strongly influences remyelination [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR72">72</xref>] and that a predominant pro-regenerative response of microglia is required for efficient myelin repair after damage [<xref ref-type="bibr" rid="CR64">64</xref>]. However, the mode(s) of action of microglia in fostering or inhibiting myelin repair was largely unclear. In the present study, by utilising a combined approach (immunohistochemistry and EM), we unequivocally show that EVs released by pro-regenerative microglia promote OPC recruitment and differentiation at LPC-induced myelin lesions, while i-EVs, derived from inflammatory microglia, block remyelination. Our study advances current knowledge by showing that (1) dark, reactive microglia are recruited at myelin lesion and release EVs, as indicated by EM, and (2) EVs are sufficient to mediate either detrimental or beneficial function on myelin forming cells, reflecting the phenotype of donor microglia, upon exogenous administration to the lesion site. EVs remain intact for a short time at the injection site, likely as a consequence of lysosomal degradation [<xref ref-type="bibr" rid="CR15">15</xref>] or cell fusion and cargo dilution [<xref ref-type="bibr" rid="CR75">75</xref>], but cause a prolonged modulation of oligodendrocytes surrounding the lesion. This is in line with a recent study showing that microglial EVs engineered to deliver an anti-inflammatory cytokine IL-4 induce a long-lasting immune modulation in the EAE model of multiple sclerosis [<xref ref-type="bibr" rid="CR15">15</xref>]. However, whether EVs with opposite action on OPCs may be generated endogenously by microglia and may be relevant for the course of de- and re-myelination in animal models of MS still remains unclear. Selective tools to manipulate endogenous EV production are needed to overcome this limitation of our study and to analyse the role of microglial EVs in a more physiological setting.</p>
</sec>
<sec id="Sec39">
<title>A1 astrocytes mediate detrimental action of i-EVs on OPCs</title>
<p id="Par77">The major finding of this paper is the demonstration that astrocytes mediate the detrimental action of inflammatory microglia-derived EVs on OPCs. While i-EVs by themselves favor differentiation of OPCs in monoculture, they cause a clear block of OPC maturation when OPCs are cocultured with astrocytes, thereby mimicking the inhibitory action of i-EVs at myelin lesion in the in vivo LPC-demyelination model. Importantly, inhibition of OPC maturation in the OPC/astrocytic co-cultures is likely paralleled by conversion of astrocytes into A1 harmful cells. Indeed, our previous work revealed that cultured astrocytes become hypertrophic and upregulate inflammatory markers when exposed to i-EVs [<xref ref-type="bibr" rid="CR95">95</xref>]. By analysing the expression and immunoreactivity of a few specific A1 and A2 markers in this study, we suggest that astrocytes acquire a harmful A1 phenotype both in vitro and in the LPC-mouse model of myelin lesion. A1 astrocytes were recently proven to slow OPC differentiation and to damage differentiated oligodendrocytes [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR99">99</xref>] and have been observed in demyelinating plaques of MS patients [<xref ref-type="bibr" rid="CR55">55</xref>]. By showing that microglial i-EVs cause A1 astrocyte transformation, we add an important piece of information towards the understanding of the mechanism possibly responsible for remyelination failure in MS. We hypothesise that demyelinating lesions may fail to remyelinate because EVs produced by chronically activated microglia block OPC differentiation by inducing harmful astrocyte conversion, thus nullifying the direct pro-myelinating action of EVs. In line with our study, previous works highlighted the detrimental effect of chronically activated astrocytes on myelin repair, by showing that depletion of reactive astrocytes at the chronic phase of EAE improves EAE clinical outcome [<xref ref-type="bibr" rid="CR62">62</xref>] and that remyelination by transplanted OPCs is less extensive in areas of demyelination that contain astrocytes than in astrocyte-free areas [<xref ref-type="bibr" rid="CR8">8</xref>]. A few proteins released by astrocytes, including CXCL10 [<xref ref-type="bibr" rid="CR67">67</xref>] and endothelin-1 [<xref ref-type="bibr" rid="CR42">42</xref>], inhibit OPC maturation and may be involved in remyelination failure. By contrast, no molecules with the capacity to damage OPCs/oligodendrocytes have been identified so far in the secretome of inflammatory microglia, which rather contains protective agents for myelin-forming cells [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].</p>
</sec>
<sec id="Sec40">
<title>EV signals driving astrocytes towards oligotoxic cells</title>
<p id="Par78">Although our analysis indicates that EVs carry the glycolipid lactosylceramide (LacCer) and S1P, known inducers of pro-inflammatory astroglial activation in EAE [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR81">81</xref>], the lipid extract of i-EVs does not drive harmful transformation in cultured astrocytes, implicating the protein and/or RNA cargoes of i-EVs in the acquisition of detrimental astroglial function. Previous studies reported that activated microglia release three mediators that are necessary and sufficient for astrocyte conversion to harmful cells, i.e. TNF-Î±, IL-1a and C1q [<xref ref-type="bibr" rid="CR55">55</xref>]. Here we show that (1) i-EVs carry the three inducers of A1 astrocytes, (2) TNF-Î± is decreased in MSC-EVs, which do not cause harmful astrocyte transformation, and (3) TNF-Î± inactivation partially inhibits the proinflammatory astrocyte response. Besides identifying TNF-Î± as a target of MSC action in microglia, this evidence implicates vesicular TNF-Î± in the astrocyte shift towards oligotoxic cells. However, other molecules may be sorted in MSC-EVs, such as TGF-Î² or FGF [<xref ref-type="bibr" rid="CR2">2</xref>], which may counteract the action of the inflammatory cargoes, preventing A1 astrocyte activation.</p>
<p id="Par79">Elevated production of TNF-Î± was previously reported in the serum, cerebrospinal fluid and brain plaques of MS patients [<xref ref-type="bibr" rid="CR59">59</xref>], correlating with disease severity or exacerbation [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. In addition, it was recently shown that TNF-Î± is mostly produced by microglia and macrophages in acute and progressive EAE, enhancing clinical disability [<xref ref-type="bibr" rid="CR91">91</xref>]. Whether the content of TNF-Î± is elevated in microglial EVs of MS patients, especially those with progressive MS, is an important question for future studies that may lead to the identification of novel disease biomarkers. In devising possible therapeutic strategies to promote myelin repair, it should be noted, however, that TNF-Î± has been attributed both detrimental and protective roles in MS. Specifically, the membrane bound form of the cytokine was shown to sustain reparative processes via activation of type 2 TNF-Î± receptor (TNFR2) in oligodendrocytes [<xref ref-type="bibr" rid="CR13">13</xref>], preventing the clinical use of TNF-Î± blockers in MS [<xref ref-type="bibr" rid="CR47">47</xref>].</p>
</sec>
<sec id="Sec41">
<title>Key role of lipids in the pro-myelinating action of EVs</title>
<p id="Par80">Another key observation of our study is that the lipid content of all types of microglial EVs has a direct impact on OPCs, directing both their recruitment and differentiation.</p>
<p id="Par81">Through measurement of sphingolipid content and the use of a potent S1P receptor antagonist S-ene-FTY720 Vinylphosphonate, we show that S1P is secreted by microglia in association with EVs and acts as an attractive guidance cue for OPCs. Although the recent use of the S1P analog fingolimod/FTY720, which activates S1P receptors, to treat MS has fueled research on the direct effects of S1P on oligodendrocytes [<xref ref-type="bibr" rid="CR38">38</xref>], to our knowledge, our data provide the first demonstration of a central role for EVs-associated S1P in OPC migration, the first key step in myelin repair. Other chemotactic molecules, such as Wnt3a [<xref ref-type="bibr" rid="CR45">45</xref>] and the endocannabinoid anandamide [<xref ref-type="bibr" rid="CR34">34</xref>] are packaged in microglial EVs, revealing the important role of EVs as vehicles of chemotactic signals [<xref ref-type="bibr" rid="CR52">52</xref>]. Through EV fractionation, we also show that lipids of all EV types drive OPC maturation, making lipid research a hotspot in the field of myelin repair. We rule out the involvement of S1P in the pro-differentiating action of EVs, since the capacity of EVs to accelerate OPC maturation was unchanged under pharmacological blockade of S1P receptors. We anticipate that identification of lipids responsible for the pro-differentiating action of microglial EVs may help to design new therapeutics to foster myelin repair.</p>
<p id="Par82">Previous studies implicated the miRNA cargo of EVs in myelin repair, rather than the lipid content. Pro-myelinating exosomes derived by peripheral immune cells were previously identified in rat serum [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Their pro-differentiating activity was partially ascribed to the delivery of miR-219 to OPCs, a microRNA that regulates multiple genes in the differentiation pathway [<xref ref-type="bibr" rid="CR76">76</xref>]. Although miR-219 is present in EVs derived from microglia and is upregulated in i-EVs [<xref ref-type="bibr" rid="CR75">75</xref>], our biochemical experiments indicate that the lipid fraction of EVs, which is free of nucleic acids, retains the ability to drive OPC maturation, arguing against a major involvement of miRNAs in the direct pro-differentiating action of microglial EVs. Nevertheless, the RNA and/or protein cargoes of EVs may indirectly regulate OPC maturation by influencing the microenvironment around the lesion.</p>
</sec>
<sec id="Sec42">
<title>The unique pro-myelinating activity of EVs derived from microglia co-cultured with MSC</title>
<p id="Par83">We show that MSC-EVs have a unique capacity to stimulate the endogenous reparative response of OPCs at myelin lesion. The pro-myelinating action of MSC-EVs exceeds that of IL4-EVs both in vitro and in vivo. This suggests that well-known effects of MSCs in EAE rely, at least in part, on the paracrine effect of MSCs on microglia phenotype and microglia communication with OPCs and astrocytes during remyelination. Further work remains to be done to define the minimal components of MSC-EVs required to drive efficient remyelination. Selected luminal components of MSC-EVs (proteins and/or RNAs) in combination with pro-differentiating lipid(s) may be assembled in EV mimetics of low complexity and with low chance of off-target effects, which may be ideal tools to develop novel therapeutic approaches in chronic MS.</p>
</sec>
</sec>
<sec sec-type="supplementary-material">
<title>Electronic supplementary material</title>
<sec id="Sec43">
<p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="401_2019_2049_MOESM1_ESM.pdf"><caption><p>Supplementary material 1 (PDF 867 kb)</p></caption></media></supplementary-material></p>
</sec>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>CC</term>
<def>
<p id="Par2">Corpus callosum</p>
</def>
</def-item>
<def-item>
<term>cryo-EM</term>
<def>
<p id="Par3">Cryo-electron microscopy</p>
</def>
</def-item>
<def-item>
<term>dpl</term>
<def>
<p id="Par4">Days post lesion</p>
</def>
</def-item>
<def-item>
<term>DTI</term>
<def>
<p id="Par5">Diffusion tensor imaging</p>
</def>
</def-item>
<def-item>
<term>DRG</term>
<def>
<p id="Par6">Dorsal root ganglion</p>
</def>
</def-item>
<def-item>
<term>ETN</term>
<def>
<p id="Par7">Etarnecept</p>
</def>
</def-item>
<def-item>
<term>EVs</term>
<def>
<p id="Par8">Extracellular vesicles</p>
</def>
</def-item>
<def-item>
<term>i-EVs</term>
<def>
<p id="Par9">EVs from inflammatory microglia</p>
</def>
</def-item>
<def-item>
<term>IL4-EVs</term>
<def>
<p id="Par10">EVs derived from IL4-treated microglia</p>
</def>
</def-item>
<def-item>
<term>MSC-EVs</term>
<def>
<p id="Par11">EVs derived from MSC-treated microglia</p>
</def>
</def-item>
<def-item>
<term>ICC</term>
<def>
<p id="Par12">Immunofluorescence</p>
</def>
</def-item>
<def-item>
<term>IHC</term>
<def>
<p id="Par13">Immunohistochemistry</p>
</def>
</def-item>
<def-item>
<term>i-microglia</term>
<def>
<p id="Par14">Inflammatory microglia</p>
</def>
</def-item>
<def-item>
<term>LPC</term>
<def>
<p id="Par15">Lysolecithin</p>
</def>
</def-item>
<def-item>
<term>MSCs</term>
<def>
<p id="Par16">Mesenchymal stem cells</p>
</def>
</def-item>
<def-item>
<term>MS</term>
<def>
<p id="Par17">Multiple sclerosis</p>
</def>
</def-item>
<def-item>
<term>OPCs</term>
<def>
<p id="Par18">Oligodendrocyte precursor cells</p>
</def>
</def-item>
<def-item>
<term>MACS</term>
<def>
<p id="Par19">Magnetic-activated cell sorting</p>
</def>
</def-item>
<def-item>
<term>MRI</term>
<def>
<p id="Par20">Magnetic resonance imaging</p>
</def>
</def-item>
<def-item>
<term>WB</term>
<def>
<p id="Par21">Western-blot</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Publisher's Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>We are grateful to Drs. Roberto Furlan (San Raffaele Scientific Institute, Milan, Italy) and Bobbi Fleiss (RMIT University, MelburneMelbourne, Australia) for helpful discussion. We thank Drs. Laura Pergoli (University of Milan, Milan, Italy) for help with NTA of EVs, Paolo Swuec (University of Milan, Milan, Italy) for cryo-electron microscopy analysis of EVs and Stefano Raffaele (University of Milan, Milan, Italy) for help with some IHC experiments. We are grateful to Dr. Francesca Garello and Prof. Enzo Terreno (University of Turin, Italy) for assistance with MRI analysis of myelin lesions. The project has been supported by GMSI 2015 to CV, AB, MF and AU and FISM/2018/R/22 to CV. MG was supported by a FISM Fellowship (2016/B/2). This study was also supported by Fondazione Cariplo grant no. 2015-0910 to MF and by Ministero dellâIstruzione, dellâUniversitÃ  e della Ricerca-MIUR project âDipartimenti di Eccellenza 2018â2022â to Dept. of Pharmacological and Biomolecular Sciences and Dept. of Neuroscience Rita Levi Montalcini.</p>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antonucci</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Turola</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Riganti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Caleo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gabrielli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Perrotta</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid metabolism</article-title>
<source/>EMBO J
          <year>2012</year>
<volume>31</volume>
<fpage>1231</fpage>
<lpage>1240</lpage>
<pub-id pub-id-type="doi">10.1038/emboj.2011.489</pub-id>
<pub-id pub-id-type="pmid">22246184</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arab</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Raffo-Romero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Van Camp</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lemaire</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Le Marrec-Croq</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Drago</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proteomic characterisation of leech microglia extracellular vesicles (EVs): comparison between differential ultracentrifugation and Optiprep density gradient isolation</article-title>
<source/>J Extracell Vesicles
          <year>2019</year>
<volume>8</volume>
<fpage>1603048</fpage>
<pub-id pub-id-type="doi">10.1080/20013078.2019.1603048</pub-id>
<pub-id pub-id-type="pmid">31069026</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baecher-Allan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kaskow</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>HL</given-names>
</name>
</person-group>
<article-title>Multiple sclerosis: mechanisms and immunotherapy</article-title>
<source/>Neuron
          <year>2018</year>
<volume>97</volume>
<fpage>742</fpage>
<lpage>768</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2018.01.021</pub-id>
<pub-id pub-id-type="pmid">29470968</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barenholz</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gibbes</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Litman</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Goll</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>A simple method for the preparation of homogeneous phospholipid vesicles</article-title>
<source/>Biochemistry
          <year>1977</year>
<volume>16</volume>
<fpage>2806</fpage>
<lpage>2810</lpage>
<pub-id pub-id-type="doi">10.1021/bi00631a035</pub-id>
<pub-id pub-id-type="pmid">889789</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pagani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Parolisi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Masferrer</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Gritti</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism-associated 16p11.2 microdeletion impairs prefrontal functional connectivity in mouse and human</article-title>
<source/>Brain J Neurol
          <year>2018</year>
<volume>141</volume>
<fpage>2055</fpage>
<lpage>2065</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awy111</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bin</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>The oligodendrocyte-specific antibody âCC1â binds Quaking 7</article-title>
<source/>J Neurochem
          <year>2016</year>
<volume>139</volume>
<fpage>181</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.13745</pub-id>
<pub-id pub-id-type="pmid">27454326</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bisht</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lacoste</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tremblay</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Dark microglia: why are they dark?</article-title>
<source/>Commun Integr Biol
          <year>2016</year>
<volume>9</volume>
<fpage>e1230575</fpage>
<pub-id pub-id-type="doi">10.1080/19420889.2016.1230575</pub-id>
<pub-id pub-id-type="pmid">28042375</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blakemore</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Gilson</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Crang</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>The presence of astrocytes in areas of demyelination influences remyelination following transplantation of oligodendrocyte progenitors</article-title>
<source/>Exp Neurol
          <year>2003</year>
<volume>184</volume>
<fpage>955</fpage>
<lpage>963</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-4886(03)00347-9</pub-id>
<pub-id pub-id-type="pmid">14769388</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boda</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Di Maria</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rosa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Abbracchio</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Buffo</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Early phenotypic asymmetry of sister oligodendrocyte progenitor cells after mitosis and its modulation by aging and extrinsic factors</article-title>
<source/>Glia
          <year>2015</year>
<volume>63</volume>
<fpage>271</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22750</pub-id>
<pub-id pub-id-type="pmid">25213035</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonavita</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gentile</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rubino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maina</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Papait</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kunderfranco</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer</article-title>
<source/>Cell
          <year>2015</year>
<volume>160</volume>
<fpage>700</fpage>
<lpage>714</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2015.01.004</pub-id>
<pub-id pub-id-type="pmid">25679762</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonfanti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gelosa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fumagalli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dimou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vigano</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tremoli</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of oligodendrocyte precursor cells expressing the GPR17 receptor in brain remodeling after stroke</article-title>
<source/>Cell Death Dis
          <year>2017</year>
<volume>8</volume>
<fpage>e2871</fpage>
<pub-id pub-id-type="doi">10.1038/cddis.2017.256</pub-id>
<pub-id pub-id-type="pmid">28594400</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brambilla</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis</article-title>
<source/>Acta Neuropathol
          <year>2019</year>
<volume>137</volume>
<fpage>757</fpage>
<lpage>783</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-019-01980-7</pub-id>
<pub-id pub-id-type="pmid">30847559</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brambilla</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ashbaugh</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Magliozzi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dellarole</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Karmally</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Szymkowski</surname>
<given-names>DE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination</article-title>
<source/>Brain J Neurol
          <year>2011</year>
<volume>134</volume>
<fpage>2736</fpage>
<lpage>2754</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awr199</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butovsky</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Landa</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kunis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ziv</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Avidan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis</article-title>
<source/>J Clin Invest
          <year>2006</year>
<volume>116</volume>
<fpage>905</fpage>
<lpage>915</lpage>
<pub-id pub-id-type="doi">10.1172/JCI26836</pub-id>
<pub-id pub-id-type="pmid">16557302</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casella</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Colombo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Finardi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Descamps</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ill-Raga</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Spinelli</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Extracellular vesicles containing IL-4 modulate neuroinflammation in a mouse model of multiple sclerosis</article-title>
<source/>Mol Ther
          <year>2018</year>
<volume>26</volume>
<fpage>2107</fpage>
<lpage>2118</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymthe.2018.06.024</pub-id>
<pub-id pub-id-type="pmid">30017878</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Cosgaya</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Reichardt</surname>
<given-names>LF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NGF controls axonal receptivity to myelination by Schwann cells or oligodendrocytes</article-title>
<source/>Neuron
          <year>2004</year>
<volume>43</volume>
<fpage>183</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2004.06.024</pub-id>
<pub-id pub-id-type="pmid">15260955</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Exosomes of BV-2 cells induced by alpha-synuclein: important mediator of neurodegeneration in PD</article-title>
<source/>Neurosci Lett
          <year>2013</year>
<volume>548</volume>
<fpage>190</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2013.06.009</pub-id>
<pub-id pub-id-type="pmid">23792198</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cherry</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Olschowka</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>OâBanion</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>Neuroinflammation and M2 microglia: the good, the bad, and the inflamed</article-title>
<source/>J Neuroinflamm
          <year>2014</year>
<volume>11</volume>
<fpage>98</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-11-98</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Gardell</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Herr</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Rivera</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2011</year>
<volume>108</volume>
<fpage>751</fpage>
<lpage>756</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1014154108</pub-id>
<pub-id pub-id-type="pmid">21177428</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarke</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Liddelow</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Chakraborty</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Munch</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Heiman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Barres</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Normal aging induces A1-like astrocyte reactivity</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2018</year>
<volume>115</volume>
<fpage>E1896</fpage>
<lpage>E1905</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1800165115</pub-id>
<pub-id pub-id-type="pmid">29437957</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colombo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Farina</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Astrocytes: key regulators of neuroinflammation</article-title>
<source/>Trends Immunol
          <year>2016</year>
<volume>37</volume>
<fpage>608</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="doi">10.1016/j.it.2016.06.006</pub-id>
<pub-id pub-id-type="pmid">27443914</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colombo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bastoni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nigro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Podini</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Finardi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Casella</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cytokines stimulate the release of microvesicles from myeloid cells independently from the P2X7 receptor/acid sphingomyelinase pathway</article-title>
<source/>Front Immunol
          <year>2018</year>
<volume>9</volume>
<fpage>204</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2018.00204</pub-id>
<pub-id pub-id-type="pmid">29467770</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>QL</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Almazan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Antel</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Role of p38MAPK in S1P receptor-mediated differentiation of human oligodendrocyte progenitors</article-title>
<source/>Glia
          <year>2014</year>
<volume>62</volume>
<fpage>1361</fpage>
<lpage>1375</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22688</pub-id>
<pub-id pub-id-type="pmid">24810969</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Domingues</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Portugal</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Socodato</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Relvas</surname>
<given-names>JB</given-names>
</name>
</person-group>
<article-title>Oligodendrocyte, astrocyte, and microglia crosstalk in myelin development, damage, and repair</article-title>
<source/>Front Cell Dev Biol
          <year>2016</year>
<volume>4</volume>
<fpage>71</fpage>
<pub-id pub-id-type="doi">10.3389/fcell.2016.00071</pub-id>
<pub-id pub-id-type="pmid">27551677</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drago</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Prada</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gabrielli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cojoc</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ATP modifies the proteome of extracellular vesicles released by microglia and influences their action on astrocytes</article-title>
<source/>Front Pharmacol
          <year>2017</year>
<volume>8</volume>
<fpage>910</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2017.00910</pub-id>
<pub-id pub-id-type="pmid">29321741</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubochet</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Adrian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Homo</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lepault</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McDowall</surname>
<given-names>AW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cryo-electron microscopy of vitrified specimens</article-title>
<source/>Q Rev Biophys
          <year>1988</year>
<volume>21</volume>
<fpage>129</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="doi">10.1017/S0033583500004297</pub-id>
<pub-id pub-id-type="pmid">3043536</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Hajj</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Savage</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Bisht</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Parent</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vallieres</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rivest</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ultrastructural evidence of microglial heterogeneity in Alzheimerâs disease amyloid pathology</article-title>
<source/>J Neuroinflamm
          <year>2019</year>
<volume>16</volume>
<fpage>87</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-019-1473-9</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischer</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Wimmer</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hoftberger</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gerlach</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Haider</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zrzavy</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disease-specific molecular events in cortical multiple sclerosis lesions</article-title>
<source/>Brain J Neurol
          <year>2013</year>
<volume>136</volume>
<fpage>1799</fpage>
<lpage>1815</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awt110</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fitzgerald</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Lederman</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Vasilieva</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Margolis</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>A system of cytokines encapsulated in extracellular vesicles</article-title>
<source/>Sci Rep
          <year>2018</year>
<volume>8</volume>
<fpage>8973</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-27190-x</pub-id>
<pub-id pub-id-type="pmid">29895824</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franklin</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Glia disease and repair-remyelination</article-title>
<source/>Csh Perspect Biol
          <year>2015</year>
<volume>7</volume>
<fpage>a020594</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a020594</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fumagalli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bonfanti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Daniele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zappelli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lecca</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Martini</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The ubiquitin ligase Mdm2 controls oligodendrocyte maturation by intertwining mTOR with G protein-coupled receptor kinase 2 in the regulation of GPR17 receptor desensitization</article-title>
<source/>Glia
          <year>2015</year>
<volume>63</volume>
<fpage>2327</fpage>
<lpage>2339</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22896</pub-id>
<pub-id pub-id-type="pmid">26228571</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fumagalli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Daniele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lecca</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Parravicini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fields</surname>
<given-names>RD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenotypic changes, signaling pathway, and functional correlates of GPR17-expressing neural precursor cells during oligodendrocyte differentiation</article-title>
<source/>J Biol Chem
          <year>2011</year>
<volume>286</volume>
<fpage>10593</fpage>
<lpage>10604</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M110.162867</pub-id>
<pub-id pub-id-type="pmid">21209081</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fumagalli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lecca</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Abbracchio</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>CNS remyelination as a novel reparative approach to neurodegenerative diseases: the roles of purinergic signaling and the P2Y-like receptor GPR17</article-title>
<source/>Neuropharmacol
          <year>2016</year>
<volume>104</volume>
<fpage>82</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.10.005</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gabrielli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Battista</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Riganti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Prada</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Antonucci</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cantone</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Active endocannabinoids are secreted on extracellular membrane vesicles</article-title>
<source/>EMBO Rep
          <year>2015</year>
<volume>16</volume>
<fpage>213</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.15252/embr.201439668</pub-id>
<pub-id pub-id-type="pmid">25568329</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ginhoux</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Greter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leboeuf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nandi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>See</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gokhan</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fate mapping analysis reveals that adult microglia derive from primitive macrophages</article-title>
<source/>Science
          <year>2010</year>
<volume>330</volume>
<fpage>841</fpage>
<lpage>845</lpage>
<pub-id pub-id-type="doi">10.1126/science.1194637</pub-id>
<pub-id pub-id-type="pmid">20966214</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giunti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Parodi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Usai</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vergani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Casazza</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bruzzone</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1</article-title>
<source/>Stem cells
          <year>2012</year>
<volume>30</volume>
<fpage>2044</fpage>
<lpage>2053</lpage>
<pub-id pub-id-type="doi">10.1002/stem.1174</pub-id>
<pub-id pub-id-type="pmid">22821677</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldmann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wieghofer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Varol</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yona</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation</article-title>
<source/>Nat Neurosci
          <year>2013</year>
<volume>16</volume>
<fpage>1618</fpage>
<lpage>1626</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3531</pub-id>
<pub-id pub-id-type="pmid">24077561</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groves</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kihara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy</article-title>
<source/>J Neurol Sci
          <year>2013</year>
<volume>328</volume>
<fpage>9</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2013.02.011</pub-id>
<pub-id pub-id-type="pmid">23518370</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gualerzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kooijmans</surname>
<given-names>SAA</given-names>
</name>
<name>
<surname>Niada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Picciolini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brini</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Camussi</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Raman spectroscopy as a quick tool to assess purity of extracellular vesicle preparations and predict their functionality</article-title>
<source/>J Extracell Vesicles
          <year>2019</year>
<volume>8</volume>
<fpage>1568780</fpage>
<pub-id pub-id-type="doi">10.1080/20013078.2019.1568780</pub-id>
<pub-id pub-id-type="pmid">30728924</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gualerzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Niada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giannasi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Picciolini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morasso</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vanna</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Raman spectroscopy uncovers biochemical tissue-related features of extracellular vesicles from mesenchymal stromal cells</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<fpage>9820</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-10448-1</pub-id>
<pub-id pub-id-type="pmid">28852131</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>The effect of injections of lysophosphatidyl choline into white matter of the adult mouse spinal cord</article-title>
<source/>J Cell Sci
          <year>1972</year>
<volume>10</volume>
<fpage>535</fpage>
<lpage>546</lpage>
<pub-id pub-id-type="pmid">5018033</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hammond</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Gadea</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dupree</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kerninon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nait-Oumesmar</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Aguirre</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Astrocyte-derived endothelin-1 inhibits remyelination through notch activation</article-title>
<source/>Neuron
          <year>2014</year>
<volume>81</volume>
<fpage>588</fpage>
<lpage>602</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2013.11.015</pub-id>
<pub-id pub-id-type="pmid">24507193</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Baffy</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome</article-title>
<source/>Postgrad Med
          <year>2017</year>
<volume>129</volume>
<fpage>872</fpage>
<lpage>888</lpage>
<pub-id pub-id-type="doi">10.1080/00325481.2017.1383819</pub-id>
<pub-id pub-id-type="pmid">28936910</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinks</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Delayed changes in growth factor gene expression during slow remyelination in the CNS of aged rats</article-title>
<source/>Mol Cell Neurosci
          <year>2000</year>
<volume>16</volume>
<fpage>542</fpage>
<lpage>556</lpage>
<pub-id pub-id-type="doi">10.1006/mcne.2000.0897</pub-id>
<pub-id pub-id-type="pmid">11083917</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hooper</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sainz-Fuertes</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lynham</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hye</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Killick</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Warley</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Wnt3a induces exosome secretion from primary cultured rat microglia</article-title>
<source/>BMC Neurosci
          <year>2012</year>
<volume>13</volume>
<fpage>144</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2202-13-144</pub-id>
<pub-id pub-id-type="pmid">23173708</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalakh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mouihate</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Androstenediol reduces demyelination-induced axonopathy in the rat corpus callosum: impact on microglial polarization</article-title>
<source/>Front Cell Neurosci
          <year>2017</year>
<volume>11</volume>
<fpage>49</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2017.00049</pub-id>
<pub-id pub-id-type="pmid">28280460</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kemanetzoglou</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Andreadou</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>CNS Demyelination with TNF-alpha Blockers</article-title>
<source/>Curr Neurol Neurosci
          <year>2017</year>
<volume>17</volume>
<fpage>36</fpage>
<pub-id pub-id-type="doi">10.1007/s11910-017-0742-1</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keough</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Yong</surname>
<given-names>VW</given-names>
</name>
</person-group>
<article-title>Experimental demyelination and remyelination of murine spinal cord by focal injection of lysolecithin</article-title>
<source/>JoVE
          <year>2015</year>
<pub-id pub-id-type="doi">10.3791/52679</pub-id>
<pub-id pub-id-type="pmid">25867716</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kimura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ohmori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kashiwakura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ohkawa</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Madoiwa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mimuro</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antagonism of sphingosine 1-phosphate receptor-2 enhances migration of neural progenitor cells toward an area of brain</article-title>
<source/>Stroke
          <year>2008</year>
<volume>39</volume>
<fpage>3411</fpage>
<lpage>3417</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.108.514612</pub-id>
<pub-id pub-id-type="pmid">18757288</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kotter</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Setzu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sim</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Van Rooijen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination</article-title>
<source/>Glia
          <year>2001</year>
<volume>35</volume>
<fpage>204</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1002/glia.1085</pub-id>
<pub-id pub-id-type="pmid">11494411</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krafft</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wilhelm</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Eremin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nestel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>von Bubnoff</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schultze-Seemann</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A specific spectral signature of serum and plasma-derived extracellular vesicles for cancer screening</article-title>
<source/>Nanomed Nanotechnol
          <year>2017</year>
<volume>13</volume>
<fpage>835</fpage>
<lpage>841</lpage>
<pub-id pub-id-type="doi">10.1016/j.nano.2016.11.016</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kriebel</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Majumdar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Senoo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ammu</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Extracellular vesicles direct migration by synthesizing and releasing chemotactic signals</article-title>
<source/>J Cell Biol
          <year>2018</year>
<volume>217</volume>
<fpage>2891</fpage>
<lpage>2910</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.201710170</pub-id>
<pub-id pub-id-type="pmid">29884750</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kucharova</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Stallcup</surname>
<given-names>WB</given-names>
</name>
</person-group>
<article-title>Distinct NG2 proteoglycan-dependent roles of resident microglia and bone marrow-derived macrophages during myelin damage and repair</article-title>
<source/>PLoS One
          <year>2017</year>
<volume>12</volume>
<fpage>e0187530</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0187530</pub-id>
<pub-id pub-id-type="pmid">29095924</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuhlmann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Miron</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wegner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Antel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bruck</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis</article-title>
<source/>Brain
          <year>2008</year>
<volume>131</volume>
<fpage>1749</fpage>
<lpage>1758</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awn096</pub-id>
<pub-id pub-id-type="pmid">18515322</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liddelow</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Guttenplan</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Bohlen</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Schirmer</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurotoxic reactive astrocytes are induced by activated microglia</article-title>
<source/>Nature
          <year>2017</year>
<volume>541</volume>
<fpage>481</fpage>
<lpage>487</lpage>
<pub-id pub-id-type="doi">10.1038/nature21029</pub-id>
<pub-id pub-id-type="pmid">28099414</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Livak</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Schmittgen</surname>
<given-names>TD</given-names>
</name>
</person-group>
<article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T))</article-title>
<source/>Methods
          <year>2001</year>
<volume>25</volume>
<fpage>402</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>
<pub-id pub-id-type="pmid">11846609</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Locatelli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Theodorou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kendirli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jordao</surname>
<given-names>MJC</given-names>
</name>
<name>
<surname>Staszewski</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Phulphagar</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mononuclear phagocytes locally specify and adapt their phenotype in a multiple sclerosis model</article-title>
<source/>Nat Neurosci
          <year>2018</year>
<volume>21</volume>
<fpage>1196</fpage>
<lpage>1208</lpage>
<pub-id pub-id-type="doi">10.1038/s41593-018-0212-3</pub-id>
<pub-id pub-id-type="pmid">30127427</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lock</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Oksenberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Steinman</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>The role of TNFalpha and lymphotoxin in demyelinating disease</article-title>
<source/>Ann Rheum Dis
          <year>1999</year>
<volume>58</volume>
<issue>Suppl 1</issue>
<fpage>I121</fpage>
<lpage>I128</lpage>
<pub-id pub-id-type="doi">10.1136/ard.58.2008.i121</pub-id>
<pub-id pub-id-type="pmid">10577988</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maimone</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Arnason</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Reder</surname>
<given-names>AT</given-names>
</name>
</person-group>
<article-title>Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis</article-title>
<source/>J Neuroimmunol
          <year>1991</year>
<volume>32</volume>
<fpage>67</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/0165-5728(91)90073-G</pub-id>
<pub-id pub-id-type="pmid">2002092</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mallucci</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Peruzzotti-Jametti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bernstock</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Pluchino</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis</article-title>
<source/>Prog Neurobiol
          <year>2015</year>
<volume>127â128</volume>
<fpage>1</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2015.02.003</pub-id>
<pub-id pub-id-type="pmid">25802011</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marrone</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Morabito</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Giustizieri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chiurchiu</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Leuti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mattioli</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice</article-title>
<source/>Nature Commun
          <year>2017</year>
<volume>8</volume>
<fpage>15292</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms15292</pub-id>
<pub-id pub-id-type="pmid">28489079</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Trauger</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Blain</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nadeau</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>JI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation</article-title>
<source/>Nat Med
          <year>2014</year>
<volume>20</volume>
<fpage>1147</fpage>
<lpage>1156</lpage>
<pub-id pub-id-type="doi">10.1038/nm.3681</pub-id>
<pub-id pub-id-type="pmid">25216636</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miron</surname>
<given-names>VE</given-names>
</name>
</person-group>
<article-title>Microglia-driven regulation of oligodendrocyte lineage cells, myelination, and remyelination</article-title>
<source/>J Leukoc Biol
          <year>2017</year>
<volume>101</volume>
<fpage>1103</fpage>
<lpage>1108</lpage>
<pub-id pub-id-type="doi">10.1189/jlb.3RI1116-494R</pub-id>
<pub-id pub-id-type="pmid">28250011</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miron</surname>
<given-names>VE</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Ruckh</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Shadrach</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination</article-title>
<source/>Nat Neurosci
          <year>2013</year>
<volume>16</volume>
<fpage>1211</fpage>
<lpage>1218</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3469</pub-id>
<pub-id pub-id-type="pmid">23872599</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miron</surname>
<given-names>VE</given-names>
</name>
<name>
<surname>Ludwin</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Darlington</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Jarjour</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Soliven</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>TE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices</article-title>
<source/>Am J Pathol
          <year>2010</year>
<volume>176</volume>
<fpage>2682</fpage>
<lpage>2694</lpage>
<pub-id pub-id-type="doi">10.2353/ajpath.2010.091234</pub-id>
<pub-id pub-id-type="pmid">20413685</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mycko</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Papoian</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Boschert</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Raine</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Selmaj</surname>
<given-names>KW</given-names>
</name>
</person-group>
<article-title>cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity</article-title>
<source/>Brain
          <year>2003</year>
<volume>126</volume>
<fpage>1048</fpage>
<lpage>1057</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awg107</pub-id>
<pub-id pub-id-type="pmid">12690045</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nash</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Linington</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Arthur</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>McClure</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>MW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional duality of astrocytes in myelination</article-title>
<source/>J Neurosci
          <year>2011</year>
<volume>31</volume>
<fpage>13028</fpage>
<lpage>13038</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1449-11.2011</pub-id>
<pub-id pub-id-type="pmid">21917786</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okabe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ikawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kominami</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nishimune</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>âGreen miceâ as a source of ubiquitous green cells</article-title>
<source/>FEBS Lett
          <year>1997</year>
<volume>407</volume>
<fpage>313</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-5793(97)00313-X</pub-id>
<pub-id pub-id-type="pmid">9175875</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olah</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Amor</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brouwer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vinet</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eggen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Biber</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of a microglia phenotype supportive of remyelination</article-title>
<source/>Glia
          <year>2012</year>
<volume>60</volume>
<fpage>306</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1002/glia.21266</pub-id>
<pub-id pub-id-type="pmid">22072381</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orlov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Myasnikov</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Andronov</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Natchiar</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Khatter</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Beinsteiner</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The integrative role of cryo electron microscopy in molecular and cellular structural biology</article-title>
<source/>Biol Cell
          <year>2017</year>
<volume>109</volume>
<fpage>81</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1111/boc.201600042</pub-id>
<pub-id pub-id-type="pmid">27730650</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paolicelli</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Bergamini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rajendran</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Cell-to-cell communication by extracellular vesicles: focus on microglia</article-title>
<source/>Neuroscience
          <year>2018</year>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2018.04.003</pub-id>
<pub-id pub-id-type="pmid">29660443</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peferoen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kipp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van der Valk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>van Noort</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Amor</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Oligodendrocyte-microglia cross-talk in the central nervous system</article-title>
<source/>Immunology
          <year>2014</year>
<volume>141</volume>
<fpage>302</fpage>
<lpage>313</lpage>
<pub-id pub-id-type="doi">10.1111/imm.12163</pub-id>
<pub-id pub-id-type="pmid">23981039</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prada</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Furlan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Legname</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Verderio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cojoc</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A new approach to follow a single extracellular vesicle-cell interaction using optical tweezers</article-title>
<source/>Biotechniques
          <year>2016</year>
<volume>60</volume>
<fpage>35</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.2144/000114371</pub-id>
<pub-id pub-id-type="pmid">26757810</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prada</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Furlan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Matteoli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Verderio</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Classical and unconventional pathways of vesicular release in microglia</article-title>
<source/>Glia
          <year>2013</year>
<volume>61</volume>
<fpage>1003</fpage>
<lpage>1017</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22497</pub-id>
<pub-id pub-id-type="pmid">23625857</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prada</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gabrielli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Turola</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Iorio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>DâArrigo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Parolisi</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Glia-to-neuron transfer of miRNAs via extracellular vesicles: a new mechanism underlying inflammation-induced synaptic alterations</article-title>
<source/>Acta Neuropathol
          <year>2018</year>
<volume>135</volume>
<fpage>529</fpage>
<lpage>550</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-017-1803-x</pub-id>
<pub-id pub-id-type="pmid">29302779</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pusic</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Kraig</surname>
<given-names>RP</given-names>
</name>
</person-group>
<article-title>Youth and environmental enrichment generate serum exosomes containing miR-219 that promote CNS myelination</article-title>
<source/>Glia
          <year>2014</year>
<volume>62</volume>
<fpage>284</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22606</pub-id>
<pub-id pub-id-type="pmid">24339157</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pusic</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Pusic</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Kraig</surname>
<given-names>RP</given-names>
</name>
</person-group>
<article-title>Environmental enrichment stimulates immune cell secretion of exosomes that promote CNS myelination and may regulate inflammation</article-title>
<source/>Cell Mol Neurobiol
          <year>2016</year>
<volume>36</volume>
<fpage>313</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="doi">10.1007/s10571-015-0269-4</pub-id>
<pub-id pub-id-type="pmid">26993508</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quigley</surname>
<given-names>EMM</given-names>
</name>
</person-group>
<article-title>Microbiota-brain-gut axis and neurodegenerative diseases</article-title>
<source/>Curr Neurol Neurosci
          <year>2017</year>
<volume>17</volume>
<fpage>94</fpage>
<pub-id pub-id-type="doi">10.1007/s11910-017-0802-6</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riboni</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Viani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bassi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Giussani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tettamanti</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Cultured granule cells and astrocytes from cerebellum differ in metabolizing sphingosine</article-title>
<source/>J Neurochem
          <year>2000</year>
<volume>75</volume>
<fpage>503</fpage>
<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0750503.x</pub-id>
<pub-id pub-id-type="pmid">10899925</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riboni</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Viani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tettamanti</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Estimating sphingolipid metabolism and trafficking in cultured cells using radiolabeled compounds</article-title>
<source/>Method Enzymol
          <year>2000</year>
<volume>311</volume>
<fpage>656</fpage>
<lpage>682</lpage>
<pub-id pub-id-type="doi">10.1016/S0076-6879(00)11110-3</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothhammer</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kenison</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Tjon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Takenaka</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>de Lima</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Borucki</surname>
<given-names>DM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2017</year>
<volume>114</volume>
<fpage>2012</fpage>
<lpage>2017</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1615413114</pub-id>
<pub-id pub-id-type="pmid">28167760</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruckh</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Shadrach</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>van Wijngaarden</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Wagers</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rejuvenation of regeneration in the aging central nervous system</article-title>
<source/>Cell Stem Cell
          <year>2012</year>
<volume>10</volume>
<fpage>96</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2011.11.019</pub-id>
<pub-id pub-id-type="pmid">22226359</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shields</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gilson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Blakemore</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Remyelination occurs as extensively but more slowly in old rats compared to young rats following fliotoxin-induced CNS demyelination</article-title>
<source/>Glia
          <year>2000</year>
<volume>29</volume>
<fpage>102</fpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1098-1136(20000101)29:1&lt;102::AID-GLIA12&gt;3.0.CO;2-1</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sim</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Penderis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation</article-title>
<source/>J Neurosci
          <year>2002</year>
<volume>22</volume>
<fpage>2451</fpage>
<lpage>2459</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-07-02451.2002</pub-id>
<pub-id pub-id-type="pmid">11923409</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rojalin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Carney</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Hazari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Knudson</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Single exosome study reveals subpopulations distributed among cell lines with variability related to membrane content</article-title>
<source/>J Extracell Vesicles
          <year>2015</year>
<volume>4</volume>
<fpage>28533</fpage>
<pub-id pub-id-type="doi">10.3402/jev.v4.28533</pub-id>
<pub-id pub-id-type="pmid">26649679</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>OâDea</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ATP redirects cytokine trafficking and promotes novel membrane TNF signaling via microvesicles</article-title>
<source/>FASEB J
          <year>2019</year>
<pub-id pub-id-type="doi">10.1096/fj.201802386r</pub-id>
<pub-id pub-id-type="pmid">30776316</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Q</given-names>
</name>
<etal></etal>
</person-group>
<article-title>LncRNA GAS5 inhibits microglial M2 polarization and exacerbates demyelination</article-title>
<source/>EMBO Rep
          <year>2017</year>
<volume>18</volume>
<fpage>1801</fpage>
<lpage>1816</lpage>
<pub-id pub-id-type="doi">10.15252/embr.201643668</pub-id>
<pub-id pub-id-type="pmid">28808113</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatischeff</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Larquet</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Falcon-Perez</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Turpin</surname>
<given-names>PY</given-names>
</name>
<name>
<surname>Kruglik</surname>
<given-names>SG</given-names>
</name>
</person-group>
<article-title>Fast characterisation of cell-derived extracellular vesicles by nanoparticles tracking analysis, cryo-electron microscopy, and Raman tweezers microspectroscopy</article-title>
<source/>J Extracell Vesicles
          <year>2012</year>
<pub-id pub-id-type="doi">10.3402/jev.v1i0.19179</pub-id>
<pub-id pub-id-type="pmid">24009887</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tremblay</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Lowery</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Majewska</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Microglial interactions with synapses are modulated by visual experience</article-title>
<source/>PLoS Biol
          <year>2010</year>
<volume>8</volume>
<fpage>e1000527</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pbio.1000527</pub-id>
<pub-id pub-id-type="pmid">21072242</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turola</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Furlan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bianco</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Matteoli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Verderio</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Microglial microvesicle secretion and intercellular signaling</article-title>
<source/>Front Physiol
          <year>2012</year>
<volume>3</volume>
<fpage>149</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2012.00149</pub-id>
<pub-id pub-id-type="pmid">22661954</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valentin-Torres</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Savarin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hinton</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Phares</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Bergmann</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Stohlman</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Sustained TNF production by central nervous system infiltrating macrophages promotes progressive autoimmune encephalomyelitis</article-title>
<source/>J Neuroinflamm
          <year>2016</year>
<volume>13</volume>
<fpage>46</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-016-0513-y</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valentine</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Kiss</surname>
<given-names>GN</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shuyu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gotoh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Murakami-Murofushi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>TC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>(S)-FTY720-vinylphosphonate, an analogue of the immunosuppressive agent FTY720, is a pan-antagonist of sphingosine 1-phosphate GPCR signaling and inhibits autotaxin activity</article-title>
<source/>Cell Signal
          <year>2010</year>
<volume>22</volume>
<fpage>1543</fpage>
<lpage>1553</lpage>
<pub-id pub-id-type="doi">10.1016/j.cellsig.2010.05.023</pub-id>
<pub-id pub-id-type="pmid">20566326</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Oosten</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Barkhof</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Scholten</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>von Blomberg</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Ader</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Polman</surname>
<given-names>CH</given-names>
</name>
</person-group>
<article-title>Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis</article-title>
<source/>Arch Neurol
          <year>1998</year>
<volume>55</volume>
<fpage>793</fpage>
<lpage>798</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.55.6.793</pub-id>
<pub-id pub-id-type="pmid">9626770</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verderio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gabrielli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giussani</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Role of sphingolipids in the biogenesis and biological activity of extracellular vesicles</article-title>
<source/>J Lipid Res
          <year>2018</year>
<volume>59</volume>
<fpage>1325</fpage>
<lpage>1340</lpage>
<pub-id pub-id-type="doi">10.1194/jlr.R083915</pub-id>
<pub-id pub-id-type="pmid">29853528</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verderio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muzio</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Turola</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bergami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Novellino</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ruffini</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Myeloid microvesicles are a marker and therapeutic target for neuroinflammation</article-title>
<source/>Ann Neurol
          <year>2012</year>
<volume>72</volume>
<fpage>610</fpage>
<lpage>624</lpage>
<pub-id pub-id-type="doi">10.1002/ana.23627</pub-id>
<pub-id pub-id-type="pmid">23109155</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Viani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Giussani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brioschi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bassi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Anelli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Tettamanti</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ceramide in nitric oxide inhibition of glioma cell growth. Evidence for the involvement of ceramide traffic</article-title>
<source/>J Biol Chem
          <year>2003</year>
<volume>278</volume>
<fpage>9592</fpage>
<lpage>9601</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M207729200</pub-id>
<pub-id pub-id-type="pmid">12515829</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voss</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Skuljec</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gudi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Skripuletz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pul</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Trebst</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterisation of microglia during de- and remyelination: can they create a repair promoting environment?</article-title>
<source/>Neurobiol Dis
          <year>2012</year>
<volume>45</volume>
<fpage>519</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2011.09.008</pub-id>
<pub-id pub-id-type="pmid">21971527</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Boza-Serrano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dunning</surname>
<given-names>CJR</given-names>
</name>
<name>
<surname>Clausen</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Lambertsen</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Deierborg</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Inflammation leads to distinct populations of extracellular vesicles from microglia</article-title>
<source/>J Neuroinflamm
          <year>2018</year>
<volume>15</volume>
<fpage>168</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-018-1204-7</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yun</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Kam</surname>
<given-names>TI</given-names>
</name>
<name>
<surname>Panicker</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>JS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinsonâs disease</article-title>
<source/>Nat Med
          <year>2018</year>
<volume>24</volume>
<fpage>931</fpage>
<lpage>938</lpage>
<pub-id pub-id-type="doi">10.1038/s41591-018-0051-5</pub-id>
<pub-id pub-id-type="pmid">29892066</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zabala</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vazquez-Villoldo</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rissiek</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gejo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Palomino</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>P2X4 receptor controls microglia activation and favors remyelination in autoimmune encephalitis</article-title>
<source/>EMBO Mol Med
          <year>2018</year>
<pub-id pub-id-type="doi">10.15252/emmm.201708743</pub-id>
<pub-id pub-id-type="pmid">29973381</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanier</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Pischiutta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Riganti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Marchesi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Turola</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fumagalli</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Bone marrow mesenchymal stromal cells drive protective M2 microglia polarization after brain trauma</article-title>
<source/>Neurotherapeutics
          <year>2014</year>
<volume>11</volume>
<fpage>679</fpage>
<lpage>695</lpage>
<pub-id pub-id-type="doi">10.1007/s13311-014-0277-y</pub-id>
<pub-id pub-id-type="pmid">24965140</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zappia</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Casazza</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pedemonte</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Benvenuto</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bonanni</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gerdoni</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy</article-title>
<source/>Blood
          <year>2005</year>
<volume>106</volume>
<fpage>1755</fpage>
<lpage>1761</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2005-04-1496</pub-id>
<pub-id pub-id-type="pmid">15905186</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>